{
  "meta": {
    "title": "Study_Design_And_Interpretation",
    "url": "https://brainandscalpel.vercel.app/study-design-and-interpretation-dd7049e8.html",
    "scrapedAt": "2025-12-01T04:07:19.562Z"
  },
  "questions": [
    {
      "text": "<p>A pediatric cardiologist decides to determine whether there is a relationship between body composition and blood pressure in a random sample of children and adolescents age 5-15.&nbsp; He used standard procedures to collect anthropometric measurements that included weight, height, hip circumference (HC), and waist circumference (WC).&nbsp; Systolic blood pressure (SBP) and diastolic pressure (DBP) readings were taken at least 3 times at 5-minute intervals after the participants had been seated, and average SBP and DBP readings were calculated based on these measurements.&nbsp; Which of the following statistical tests is adequate to determine whether there is a relationship between WC and average DBP?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Analysis of variance"
        },
        {
          "id": 2,
          "text": "Chi-square test"
        },
        {
          "id": 3,
          "text": "Correlation analysis"
        },
        {
          "id": 4,
          "text": "Meta-analysis"
        },
        {
          "id": 5,
          "text": "Two-sample t-test"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Statistical tests</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t35860\"><table class=\"table-default-style table-footer-only-style\"><tbody><tr><td></td><td></td><td colspan=\"2\"><p align=\"center\"><strong>Dependent variable</strong></p></td></tr><tr><td></td><td></td><td><p align=\"center\"><em>Qualitative (categorical)</em></p></td><td><p align=\"center\"><em>Quantitative </em></p></td></tr><tr><td rowspan=\"2\"><p align=\"center\"><strong>Independent variable</strong></p></td><td><p align=\"center\"><em>Qualitative (categorical)</em></p></td><td><p align=\"center\">Chi-square, logistic regression*</p></td><td><p align=\"center\"><em>t</em> test, ANOVA, linear regression</p></td></tr><tr><td><p align=\"center\"><em>Quantitative</em></p></td><td><p align=\"center\">Logistic regression*</p></td><td><p align=\"center\">Correlation, linear regression</p></td></tr><tr><td colspan=\"4\"><p>*Dependent variable must be dichotomous.</p><p><strong>ANOVA</strong> = &nbsp;analysis of variance.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>Variables are broadly classified as qualitative (ie, categorical) or quantitative (ie, continuous) based on their scale of measurement.&nbsp; <strong>Qualitative variables</strong> (eg, type of treatment, blood type) represent categories or groups whereas <strong>quantitative variables</strong> (eg, temperature, glucose levels) represent numerical values.&nbsp; The scale of measurement of the dependent (eg, outcome) and independent (eg, exposures, risk factors) variables in a study determines the correct statistical test for any given situation.</p><p><strong>Correlation analysis</strong> is a statistical technique <strong>used to assess</strong> the strength and direction of a <strong>linear relationship between 2 quantitative variables</strong> (often, but not always, a dependent and an independent variable).&nbsp; In this study:</p><ul><li>The quantitative dependent variable was diastolic pressure (DBP).</li><li>The quantitative independent variable was waist circumference (WC).</li></ul><p>Correlation analysis can determine whether there is a relationship between DBP and WC.&nbsp; A statistically significant <a href=\"7183\">correlation coefficient</a> indicates that DBP and WC have a linear relationship (ie, the null hypothesis is rejected) that is either positive (as WC increases, DBP increases) or negative (as WC increases, DBP decreases).</p><p><strong>(Choice A)</strong>&nbsp; The analysis of variance (ANOVA) test compares the mean of a quantitative variable of &#8805;3 independent groups, as in a study comparing serum ferritin concentrations (ie, quantitative variable) in children (age 0-12), adolescents (age 13-17), adults (age 18-59), and seniors (age &#8805;60).</p><p><strong>(Choice B)</strong>&nbsp; The chi-square test evaluates the association between 2 categorical variables, as in a study evaluating the association between sex (ie, &#x22;male&#x22; and &#x22;female&#x22;) and myocardial infarction (ie, presence of myocardial infarction, absence of myocardial infarction).</p><p><strong>(Choice D)</strong>&nbsp; Meta-analysis is a quantitative statistical technique used to combine and analyze data from several studies to conduct an analysis with a greater statistical power than that of the individual studies.</p><p><strong>(Choice E)</strong>&nbsp; The two-sample <em>t</em>-test compares the mean of a quantitative variable between 2 groups, as in a study comparing serum ferritin concentrations (ie, quantitative variable) in male and female patients.</p><p><strong>Educational objective:</strong><br>Correlation analysis is a statistical technique used to describe the strength and direction of a linear relationship between 2 quantitative variables.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17739",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A new biomarker has been shown to allow for the early detection of non-small cell lung carcinoma.&nbsp; A preliminary analysis on a cohort study of this new test demonstrates that its use prolongs survival of lung cancer patients by 3 months when compared to the survival of patients diagnosed by conventional methods.&nbsp; A secondary analysis reveals no difference in 6-month mortality rates between the 2 groups.&nbsp; Which of the following factors most likely explains the study results?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Confounding"
        },
        {
          "id": 2,
          "text": "Lead-time bias"
        },
        {
          "id": 3,
          "text": "Length-time bias"
        },
        {
          "id": 4,
          "text": "Measurement bias"
        },
        {
          "id": 5,
          "text": "Observer bias"
        },
        {
          "id": 6,
          "text": "Rare disease assumption"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Bias</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"1392\" src=\"https://www.uworld.com/media/L19161.jpg\" ></p><p><strong>Lead-time bias</strong> should always be considered when evaluating any screening test.&nbsp; Lead-time bias is an <strong>apparent increase in survival time</strong> among patients undergoing screening when they actually have an <strong>unchanged prognosis</strong>.&nbsp; Patients screened with more sensitive tests may appear to live longer only because the disease was detected earlier than had it been diagnosed clinically.&nbsp; The overall length of time from disease onset to death actually remains the same with or without the earlier screening.&nbsp; To determine the actual effectiveness of the screening program, it is necessary to follow up patients for periods that are <strong>longer</strong> than the apparent increase in survival time, and then to estimate and compare mortality rates among patients who have undergone the additional screening and those who have not.</p><p>In this case, patients screened by the new test appeared to have increased their survival time by 3 months when compared to those diagnosed by conventional methods.&nbsp; However, there was <strong>no difference in 6-month mortality</strong> rate between the 2 groups, which indicates that there is no actual benefit to the screening program.</p><p><strong>(Choice A)</strong>&nbsp; Confounding distorts the relationship between risk factors and the disease of interest, and can wholly or partially account for the observed effect.&nbsp; Although the results of this study could be potentially confounded, there is no information on how potential confounders were treated during the design or analysis stage of the study.</p><p><strong>(Choice C)</strong>&nbsp; <a href=\"1782\">Length-time bias</a> occurs when subjects with a rapidly progressive form of disease are less likely to be detected by screening compared to those with slowly progressive disease.&nbsp; This bias tends to overstate the beneficial effects of screening on length of survival and mortality.&nbsp; In this case, there is no indication that the patients identified by the new test have more benign forms of lung cancer.</p><p><strong>(Choices D and E)</strong>&nbsp; Measurement bias and observer bias refer to the misclassification of outcome and/or exposure (eg, labeling diseased as non-diseased and vice versa) and are related to poor study design.&nbsp; The scenario described does not mention how the study was conducted.</p><p><strong>(Choice F)</strong>&nbsp; Rare disease assumption refers to the practice of approximating the odds ratio and relative risk when conducting a case-control study for rare diseases.&nbsp; According to the assumption, the odds ratio approximates relative risk when disease incidence is low (eg, &lt;10%).</p><p><strong>Educational objective:</strong><br>Lead-time bias occurs when a new test diagnoses a condition earlier than conventional studies, causing an apparent increase in survival time despite no improvement in overall mortality.&nbsp; Long-term mortality rates, not survival times, should be considered for measuring the effect of early screening and treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1170",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A genome-wide association study (GWAS) of rheumatoid arthritis (RA) is performed in a cohort of Portuguese patients, including 907 cases with RA and 1,524 controls without RA.&nbsp; Logistic regression is used to test the association between RA and hundreds of thousands of loci.&nbsp; These association results are then compared with data from a European GWAS cohort of 4,036 patients with RA and 6,959 patients without RA.&nbsp; Finally, the Portuguese and European study results are combined into a meta-analysis.&nbsp; Based on these data, the investigators identify 3 new loci that are associated with RA based on a significance level threshold of 5 &times; 10<font size=\"2\"><sup>&#8722;8</sup></font>:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td rowspan=\"2\"></td><td colspan=\"2\"><strong>European study</strong></td><td colspan=\"2\"><strong>Portuguese study</strong></td><td colspan=\"2\"><strong>Meta-analysis</strong></td></tr><tr><td><strong>Odds ratio</strong></td><td><strong><em>p</em>-value</strong></td><td><strong>Odds ratio</strong></td><td><strong><em>p</em>-value</strong></td><td><strong>Odds ratio</strong></td><td><strong><em>p</em>-value</strong></td></tr><tr><td>Locus 1</td><td>0.53</td><td>8.36 &times; 10<font size=\"2\"><sup>&#8722;7</sup></font></td><td>0.61</td><td>0.013</td><td>0.55</td><td>3.5 &times; 10<font size=\"2\"><sup>&#8722;8</sup></font></td></tr><tr><td>Locus 2</td><td>1.16</td><td>8.40 &times; 10<font size=\"2\"><sup>&#8722;7</sup></font></td><td>1.14</td><td>0.019</td><td>1.16</td><td>4.9 &times; 10<font size=\"2\"><sup>&#8722;8</sup></font></td></tr><tr><td>Locus 3</td><td>1.63</td><td>0.0000015</td><td>1.77</td><td>0.0074</td><td>1.66</td><td>4.1 &times; 10<font size=\"2\"><sup>&#8722;8</sup></font></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Previous studies had identified 30 loci that accounted for &lt;35% of disease heritability for RA.&nbsp; Which of the following statements is correct regarding this study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Combining the results of the European and Portuguese studies into a meta-analysis decreases the power"
        },
        {
          "id": 2,
          "text": "Logistic regression is used because there is a stepwise increase in the strength of association from Locus 1 to Locus 3"
        },
        {
          "id": 3,
          "text": "The association between Locus 1 and RA in the meta-analysis is not statistically significant because the odds ratio is &lt;1"
        },
        {
          "id": 4,
          "text": "The threshold used for the p-value in the meta-analysis is 5 &times; 10&#8722;8 because of the large number of loci studied"
        },
        {
          "id": 5,
          "text": "With this meta-analysis, the 33 identified loci account for most disease heritability in RA"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > P-value and confidence interval</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Genome-wide association studies</strong> (GWAS) are typically case-control studies that involve scanning thousands of genetic markers in subjects with and without a disease to identify <strong>associations between genetic variants</strong> (eg, loci) and that <strong>disease</strong>.&nbsp; GWAS often use single-nucleotide polymorphisms (SNPs), with several million SNPs analyzed on 1 microscope slide.</p><p>In this case, GWAS are used to analyze <strong>hundreds of thousands of loci</strong> in Portuguese patients with and without rheumatoid arthritis (RA).&nbsp; The results are compared to those from a larger European cohort; both studies are then combined in a meta-analysis.&nbsp; A few loci have SNPs with an allele that is significantly more common among patients with RA than those without RA; these loci are therefore associated with RA.</p><p>Whenever <strong>multiple tests</strong> are performed simultaneously (eg, analyzing thousands of loci), the possibility of <strong>false-positive results</strong> increases.&nbsp; Using a much <strong>smaller threshold for the <em>p</em>-value</strong> is a method to minimize this.&nbsp; Traditionally, a <em>p</em>-value &lt;5% is considered statistically significant.&nbsp; However, if 100,000 loci are studied at that 5% (ie, 0.05, 5 &times; 10<font size=\"2\"><sup>&#8722;2</sup></font>) level, then 100,000 &times; 0.05 = 5,000 false positives would be expected.&nbsp; With a much smaller <em>p</em>-value, this number decreases substantially.&nbsp; For this reason, a <em>p</em>-value of 5 &times; 10<font size=\"2\"><sup>&#8722;8</sup></font> (&#x22;genome-wide <em>p</em>-value&#x22;), as seen here, is often chosen in GWAS.</p><p><strong>(Choice A)</strong>&nbsp; A meta-analysis combines results from different studies, thereby increasing sample size, which increases power (eg, to detect statistical differences between groups).</p><p><strong>(Choice B)</strong>&nbsp; Logistic regression was used because it analyzes the association between exposures (eg, multiple loci) and binary outcomes (eg, yes = cases with RA; no = controls without RA).</p><p><strong>(Choice C)</strong>&nbsp; An odds ratio (OR) &lt;1 does not imply a lack of statistically significant association.&nbsp; If an OR &gt;1 means that patients with RA have <em>higher</em> odds of having a specific locus compared to those without RA (ie, risk factor), an OR &lt;1 means that patients with RA have <em>lower</em> odds of having that specific locus (ie, protective factor).&nbsp; The OR for the association between Locus 1 and RA is statistically significant because its <em>p</em>-value (3.5 &times; 10<font size=\"2\"><sup>&#8722;8</sup></font>) is less than the genome-wide <em>p</em>-value (5 &times; 10<font size=\"2\"><sup>&#8722;8</sup></font>).</p><p><strong>(Choice E)</strong>&nbsp; GWAS help explain disease heritability (ie, effect of genotypic differences on phenotypic differences).&nbsp; Although this study identified 3 new loci, there is no indication that the full&nbsp;group of 33 loci will explain most RA disease heritability.&nbsp; GWAS have identified many genes associated with specific conditions, but these genes only seem to explain a small amount of the variance (&#x22;missing heritability&#x22;).</p><p><strong>Educational objective:</strong><br>Genome-wide association studies aim to identify associations between thousands of genetic variants and a disease.&nbsp; Because of the increased risk of false-positive results when multiple tests are performed simultaneously, a smaller genome-wide <em>p</em>-value is typically used.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17538",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study determines that the mean blood cholesterol level is 195 mg/dL in 200 non-diabetic hospitalized patients and 210 mg/dL in 180 diabetic hospitalized patients.&nbsp; The probability that the observed difference is due to chance alone is reported to be 5%.&nbsp; There is also a 20% probability of concluding that there is no difference in blood cholesterol level when there is one in reality.&nbsp; What is the power of the study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "0.05"
        },
        {
          "id": 2,
          "text": "0.20"
        },
        {
          "id": 3,
          "text": "0.50"
        },
        {
          "id": 4,
          "text": "0.80"
        },
        {
          "id": 5,
          "text": "0.95"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Power and sample size</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>The <strong>power</strong> of a study is the ability of a study to detect a difference between groups when such a difference truly exists.&nbsp; Power is related to <strong>type II error (&#946;)</strong>, which is the probability of concluding there is no difference between groups when one truly exists.&nbsp; Mathematically, power is given by:</p><blockquote><strong>Power = 1 &ndash; &#946;</strong></blockquote><p>In this example, the power of the study is the probability of detecting a difference in blood cholesterol level between diabetics and non-diabetics if there is a real difference.&nbsp; The probability of concluding that there is no difference in blood cholesterol level when in reality there is one is given as 20%; this corresponds to the definition of &#946; (ie, &#946; = 0.20 in this example).&nbsp; Therefore:</p><blockquote>Power = 1 &ndash; &#946; = 1 &ndash; 0.20 = 0.80</blockquote><p><strong>(Choice A)</strong>&nbsp; Type I error (&#945;) describes the probability of seeing a difference when there is no difference in reality.&nbsp; The value of &#945; is generally compared to the probability that the observed difference is due to chance alone (a simplified explanation of the p-value).&nbsp; In this example, the probability that the observed difference between diabetic and nondiabetic patients is due to chance alone is given as 5% (0.05).</p><p><strong>(Choices B and E)</strong>&nbsp; Type II error (&#946;) is 0.20, as explained above.&nbsp; The value 0.95 corresponds to (1 &ndash; &#945;), but power is given by (1 &ndash; &#946;).</p><p><strong>Educational objective:</strong><br>The power of a study indicates the probability of seeing a difference when there is one.&nbsp; The formula is Power = 1 &ndash; &#946;, where &#946; is the type II error rate.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1204",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A meta-analysis of several trials on the effect of cocoa intake on systolic blood pressure (SBP) revealed the following results:</p><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\"><tbody align=\"center\"><tr><td><strong>Study</strong></td><td><strong>Mean SBP in cocoa group &#8722; mean SBP in control group (mm Hg)<br>[95% confidence interval]</strong></td></tr><tr><td>1</td><td>&#8722;5.2 [&#8722;7.3, &#8722;3.4]</td></tr><tr><td>2</td><td>1.6 [&#8722;5.3, 10.4]</td></tr><tr><td>3</td><td>&#8722;4.2 [&#8722;8.1, &#8722;2.7]</td></tr><tr><td>4</td><td>&#8722;2.9 [&#8722;4.1, &#8722;1.4]</td></tr><tr><td>5</td><td>&#8722;2.8 [&#8722;5.2, &#8722;1.1]</td></tr><tr><td>6</td><td>0.8 [0.1, 1.2]</td></tr><tr><td>7</td><td>1.0 [&#8722;1.2, 3.3]</td></tr><tr><td><strong>Total</strong></td><td>&#8722;<strong>2.2 [</strong>&#8722;<strong>2.7,</strong>&nbsp;&#8722;<strong>1.3]</strong></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>All the trials evaluated the difference in SBP at 2 weeks.&nbsp; Based on the data, which of the following is the most appropriate conclusion?</p>",
      "choices": [
        {
          "id": 1,
          "text": "A higher mean SBP was seen in the cocoa groups overall"
        },
        {
          "id": 2,
          "text": "Cocoa intake should be recommended for blood pressure management"
        },
        {
          "id": 3,
          "text": "Cocoa intake was associated with a statistically significant decrease in SBP"
        },
        {
          "id": 4,
          "text": "Studies 2, 6, and 7 showed a statistically significant increase in SBP"
        },
        {
          "id": 5,
          "text": "There was no statistically significant change in SBP overall"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Meta analysis</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>A <strong>meta-analysis</strong> groups the results of several trials (ideally, high-quality randomized controlled trials) to increase statistical power and provide an overall estimate of the effect of an exposure (eg, cocoa intake) on an outcome (eg, systolic blood pressure [SBP]).&nbsp; The individual results of the trials are assessed and weighted to obtain a <strong>pooled effect estimate</strong>.&nbsp; In this example, the meta-analysis showed an overall change in mean SBP of &#8722;2.2 mm Hg (ie, decrease in SBP) in the cocoa intake group compared to the control group.&nbsp; The 95% confidence interval (CI) was &#8722;2.7 to &#8722;1.3 mm Hg, indicating a statistically significant difference because the CI does not include the null value (explained below).</p><p>CIs give a range of plausible values for an unknown parameter (eg, difference between 2 mean SBPs) based on results from a sample.&nbsp; If the <strong>CI does not include the null value</strong>, then the result is <strong>statistically significant</strong>; if it crosses the null value, then the result is not statistically significant.&nbsp; All CIs have a null value, but the null value is not the same for all CIs.&nbsp; For an odds ratio or a relative risk (RR), the null value is 1 because these statistics are ratios (ie, RR = 1 represents no difference in risk between the groups).&nbsp; However, if the parameter of interest is a <strong>difference </strong>(eg, difference in mean SBP between cocoa intake and control groups), then the <strong>null value is 0</strong> because that represents no difference between the groups.</p><p>In this case, the 95% CI of [&#8722;2.7, &#8722;1.3] does not include the null value of 0 and therefore the result is <strong>statistically significant</strong>.&nbsp; In summary, cocoa intake was associated with a statistically significant decrease in SBP.</p><p><strong>(Choices A and E)</strong>&nbsp; The overall mean change in SBP was negative at &#8722;2.2 mm Hg, reflecting a lower SBP in the cocoa group compared to the control group.&nbsp; The change was statistically significant.</p><p><strong>(Choice B)</strong>&nbsp; Although there was a statistically significant decrease in SBP in the cocoa intake group, the clinical significance may be limited as the absolute SBP decrease is only about 2 mm Hg.&nbsp; Furthermore, the trials measured SBP at 2 weeks, so it is possible that the effect of cocoa intake on SBP was short-lived.&nbsp; Finally, no information is provided regarding adverse effects of cocoa intake.</p><p><strong>(Choice D)</strong>&nbsp; Given that the CI crossed the null value in studies 2 and 7, there was no statistically significant difference between the groups in these studies.</p><p><strong>Educational objective:</strong><br>A meta-analysis groups results of several trials to increase statistical power and provide an overall pooled effect estimate.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "9985",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A physician is conducting a double-blind randomized controlled trial to determine the effect of a new cream in reducing the risk of relapse in chronic recurrent atopic dermatitis.&nbsp; A total of 30 patients with moderate to severe atopic dermatitis who were experiencing a flare are randomly divided into 2 groups: 15 patients will receive the new cream, and 15 patients will receive emollient alone.&nbsp; The rate of relapse after 2 weeks of treatment is 25% in the group who received the new cream and 50% in the group who received emollient alone.&nbsp; However, the difference is found to be not statistically significant (<em>p</em> = 0.14).&nbsp; The physician concludes that use of the new cream does not reduce the risk of relapse in chronic recurrent atopic dermatitis.&nbsp; Which of the following is most likely to explain the results of the study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Ascertainment bias"
        },
        {
          "id": 2,
          "text": "Confounding bias"
        },
        {
          "id": 3,
          "text": "Ecologic fallacy"
        },
        {
          "id": 4,
          "text": "Insufficient statistical power"
        },
        {
          "id": 5,
          "text": "Recall bias"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Power and sample size</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Statistical power</strong> represents a study&#39;s <strong>strength to detect a difference</strong> (ie, effect size) between treatment groups when one truly exists.&nbsp; It <strong>depends</strong> on <strong>sample size</strong> (among other factors): studies with <strong>greater sample sizes</strong> have <strong>greater power</strong> than studies with smaller sample sizes.&nbsp; An excessively large sample size may determine that a clinically irrelevant difference between groups is statistically significant (ie, <em>p</em> &lt; 0.05), while an inappropriately small sample may determine that a clinically relevant difference between groups is statistically insignificant (ie, <em>p</em> &gt; 0.05).</p><p>In this case, the rate of relapse in the group receiving the new cream is 25% and the rate in the group receiving the emollient alone is 50%.&nbsp; This represents a <strong>relative risk reduction (RRR) of 50%</strong> (ie, [50% &#8722; 25%] / 50%); therefore, the new cream reduced the risk of relapse by 50% (ie, effect size) compared to emollient alone.&nbsp; A 50% risk reduction may be considered <strong>clinically relevant</strong>; however, it was <strong>not statistically significant</strong> (ie, <em>p</em> = 0.14 &gt; 0.05) in the study.</p><p>The most likely explanation is that the sample size (ie, 15 per group) provided <strong>insufficient power</strong> to detect the observed difference between groups (ie, effect size, RRR = 50%).&nbsp; A larger sample size would increase the power of the study (ie, its ability to detect the difference), and the <em>p</em>-value would reach statistical significance (ie, <em>p</em> &lt; 0.05).</p><p><strong>(Choice A)</strong>&nbsp; Ascertainment bias occurs when the results of a study are distorted by awareness of treatment assignment, as in an unblind study.&nbsp; This study is double-blinded, thereby minimizing potential ascertainment bias.</p><p><strong>(Choice B)</strong>&nbsp; Confounding distorts the relationship between exposures (eg, treatments) and the outcome (eg, disease) of interest, and can wholly or partially account for observed effects.&nbsp; This study is a randomized trial, thereby minimizing potential confounding bias by generating groups that are comparable with respect to known and unknown confounding variables.</p><p><strong>(Choice C)</strong>&nbsp; Ecological fallacy occurs when conclusions are made about individuals based on studies where the unit of analysis is a group (ie, the conclusions of a study&nbsp;assessing population groups do not necessarily apply to individuals).&nbsp; In this study, the unit of analysis is the individual, not the group.</p><p><strong>(Choice E)</strong>&nbsp; Recall bias results from the inaccurate recollection of past exposure status.&nbsp; It is a potential problem for case-control studies, particularly when questionnaires are used to inquire about distant past exposure.&nbsp; However, this study is an experiment in which patients are exposed to treatments and then assessed for the outcome.</p><p><strong>Educational objective:</strong><br>An inappropriately small sample will fail to identify important clinically significant differences as statistically significant because of a lack of sufficient statistical power.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "18266",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Public health officials involved in developing nutritional guidelines commission a study to determine how dietary eating patterns influence total body iron stores in children age 5-17.&nbsp; As part of the study, researchers want to assess how 2 independent variables, red meat consumption and egg consumption (both&nbsp;reported in units of ounces/week), affect serum ferritin concentrations&nbsp;while adjusting for age and gender.&nbsp; Which of the following statistical techniques is most helpful for determining the association between the study variables?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Analysis of variance"
        },
        {
          "id": 2,
          "text": "Meta-analysis"
        },
        {
          "id": 3,
          "text": "Odds ratio"
        },
        {
          "id": 4,
          "text": "Regression analysis"
        },
        {
          "id": 5,
          "text": "Relative risk"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Statistical tests</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t35860\"><table class=\"table-default-style table-footer-only-style\"><tbody><tr><td></td><td></td><td colspan=\"2\"><p align=\"center\"><strong>Dependent variable</strong></p></td></tr><tr><td></td><td></td><td><p align=\"center\"><em>Qualitative (categorical)</em></p></td><td><p align=\"center\"><em>Quantitative </em></p></td></tr><tr><td rowspan=\"2\"><p align=\"center\"><strong>Independent variable</strong></p></td><td><p align=\"center\"><em>Qualitative (categorical)</em></p></td><td><p align=\"center\">Chi-square, logistic regression*</p></td><td><p align=\"center\"><em>t</em> test, ANOVA, linear regression</p></td></tr><tr><td><p align=\"center\"><em>Quantitative</em></p></td><td><p align=\"center\">Logistic regression*</p></td><td><p align=\"center\">Correlation, linear regression</p></td></tr><tr><td colspan=\"4\"><p>*Dependent variable must be dichotomous.</p><p><strong>ANOVA</strong> = &nbsp;analysis of variance.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>Variables are broadly classified as qualitative (ie, categorical) or quantitative (eg, continuous) based on their scale of measurement.&nbsp; <strong>Qualitative variables</strong> (eg, type of treatment, blood type) <strong>represent categories or groups</strong> whereas <strong>quantitative variables</strong> (eg, temperature, glucose levels) <strong>represent numerical values</strong>.&nbsp; The scale of measurement of the dependent (eg, outcome) and independent (eg, exposures, risk factors) variables in a study determines the correct statistical test.</p><p><strong>Regression analysis</strong> is used to describe the <strong>association between 1 or more independent variables</strong> (eg, exposures, risk factors), which may be quantitative or qualitative, and&nbsp;1 quantitative dependent variable (ie, <strong>a&nbsp;quantitative outcome</strong> [eg, laboratory values]) while adjusting for other variables of interest.&nbsp; In this study:</p><ul><li><p>The quantitative dependent variable was serum ferritin concentration.</p></li><li><p>The independent variables were consumption of red meat and eggs reported in ounces/week (2 quantitative variables).</p></li><li><p>The effect of the main independent variables (eg, consumption of red meat and eggs) on the dependent variable (eg, serum ferritin concentration) is adjusted to account for the effects of other independent variables, which are called adjustment variables (eg, age, gender).&nbsp; Controlling for these variables reduces the potential confounding.</p></li></ul><p>Calculation of a regression line (eg, line of best fit) can then determine whether dietary consumption of red meat and eggs has a statistically significant effect on serum ferritin concentrations (after adjusting for age and gender).</p><p><strong>(Choice A)</strong>&nbsp; The analysis of variance (ANOVA) test compares the mean of a quantitative variable of &#8805;3 independent groups.&nbsp; For example, it could be used in a study comparing serum ferritin concentrations (ie, quantitative variable) in children (age 0-12), adolescents (age 13-17), adults (age 18-59), and seniors (age &#8805;60).</p><p><strong>(Choice B)</strong>&nbsp; Meta-analysis is a quantitative statistical technique used to combine and analyze data from several studies to conduct an analysis with a greater statistical power than that of the individual studies.</p><p><strong>(Choices C and E)</strong>&nbsp; The odds ratio (OR) and the relative risk (RR) measure the strength of association between 2 categorical variables:&nbsp;a categorical risk factor&nbsp;(eg, smoker or&nbsp;nonsmoker) and a categorical outcome/disease (eg, presence or absence of myocardial infarction).&nbsp; The OR is used in case-control studies whereas the RR is used in cohort studies.</p><p><strong>Educational objective:</strong><br>A regression analysis is a statistical technique used to describe the effect that&nbsp;1 or more independent variables (eg, exposures, risk factors), which may be quantitative or qualitative, can have on 1 quantitative dependent variable (ie, outcome).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17737",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study aims to investigate the effectiveness of the topical application of tetracycline ointment in the prevention of surgical-site infection associated with resection of advanced oral cavity cancer.&nbsp; Fifty patients who underwent locoregional resection were assigned by chance to receive standard care alone or tetracycline-ointment in addition to standard care.&nbsp; The patients were then followed for 1 month and the number and severity of surgical-site infections were recorded for each group.&nbsp; Which of the following best describes the study design?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Case-control study"
        },
        {
          "id": 2,
          "text": "Crossover design"
        },
        {
          "id": 3,
          "text": "Prospective cohort study"
        },
        {
          "id": 4,
          "text": "Randomized control trial"
        },
        {
          "id": 5,
          "text": "Retrospective cohort study"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Research studies</strong> are classified as observational studies (eg, cross-sectional, case control, cohort) or experimental studies (eg, randomized control trials, factorial, crossover), depending on how much control a researcher has over the independent variables (eg, risk factors/exposures, interventions) in a study.&nbsp; The main differences between these 2 types of study designs are as follows:</p><ul><li><p>In <strong>observational designs</strong>, the researcher <strong>observes the effect</strong> of naturally occurring risk factors/exposures on outcomes of interest.</p></li><li><p>In <strong>experimental designs</strong>, the researcher <strong>randomly assigns interventions</strong> to potential participants to assess the effect of the controlled interventions.</p></li></ul><p>A <strong>randomized control trial</strong> is one of the simplest subtypes of experimental designs; it is an experiment in which <strong>participants</strong> are <strong>randomly allocated</strong> to <strong>&#8805;2 groups</strong> to assess the effect of <strong>specific interventions</strong> (eg, treatments).&nbsp; In this example, 50 patients who underwent surgical resection of advanced oral cavity cancer were assigned by chance into either a tetracycline-ointment treatment group or a standard-of-care control group. The effectiveness of the topical application of tetracycline ointment for prevention of surgical-site infection was then assessed by recording the incidence and severity of infections in each group.</p><p><strong>(Choice A)</strong>&nbsp; A case-control study is a type of observational study in which potential participants are initially identified as cases or controls according to outcome status (ie, developing the disease or condition of interest); the 2 groups are then assessed on their past exposure to specific risk factors.</p><p><strong>(Choice B)</strong>&nbsp; A <a href=\"7793\">crossover study</a> is an experiment in which subjects are exposed to different treatments or exposures sequentially.&nbsp; In the above scenario, patients are exposed to a single treatment only.</p><p><strong>(Choices C and E)</strong>&nbsp; In prospective cohort studies, exposure status is determined in the present and patients are tracked over time for development of the outcome of interest; in retrospective cohort studies, exposure status is determined at a particular point in the past, and participants are tracked retrospectively, typically through their medical records.&nbsp; However, participants in cohort studies already have a definite exposure status; they are not randomly assigned to exposure groups as in the above example.</p><p><strong>Educational objective:</strong><br>A randomized control trial is an experiment in which participants are randomly allocated to &#8805;2 groups to assess the effect of specific interventions (eg, treatments).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "13478",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study is conducted to assess the effect of beta-blocker therapy in patients with acute myocardial infarction (MI).&nbsp; The study found that 20 patients out of 90 who took a beta-blocker during the week prior to developing an MI had a major arrhythmia event during hospitalization.&nbsp; The study also determined that 30 patients out of 70 who did not take any beta-blocker developed a major arrhythmia.&nbsp; What was the odds ratio of developing major arrhythmia in patients who took beta-blockers compared to those who did not take beta-blockers?</p>",
      "choices": [
        {
          "id": 1,
          "text": "(20 &times; 30) / (70 &times; 40)"
        },
        {
          "id": 2,
          "text": "(20 &times; 40) / (70 &times; 30)"
        },
        {
          "id": 3,
          "text": "(20 &times; 70) / (30 &times; 40)"
        },
        {
          "id": 4,
          "text": "(20 / 50) / (70 / 110)"
        },
        {
          "id": 5,
          "text": "(20 / 90) / (30 / 70)"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Odds ratio</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>The odds of an event occurring are defined as the probability of that event happening divided by the probability of the event not happening.&nbsp; For instance, when <a href=\"4953\">rolling dice</a>, the probability of rolling a one is 1/6, whereas the probability of rolling any other number is 5/6.&nbsp; Therefore, the odds of rolling a one are 1/5.</p><p>The <strong>odds ratio (OR)</strong> is a measure of association that compares the odds of an outcome occurring based on exposure status.&nbsp; In this case, it represents the odds that the outcome (eg, major arrhythmia) occurred in the presence of the exposure (eg, beta blocker use) compared with the odds that the outcome occurred in the absence of that exposure.&nbsp; The OR can be calculated using a standard contingency table (with exposures in the rows and outcomes in the columns).</p><p><img draggable=\"false\" id=\"1584\" src=\"https://www.uworld.com/media/L20024.jpg\" ></p><p>Odds of developing major arrhythmia in exposed group = 20/70<br>Odds of developing major arrhythmia in unexposed group = 30/40<br>(note that the total number of people in the exposed and unexposed groups is <strong>not</strong> used to calculate odds, unlike calculating probabilities)</p><p>Therefore, the OR of developing a major arrhythmia in patients who took beta blockers compared with those who did not is as follows:</p><blockquote><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td align=\"center\">(a/b) / (c/d) = (20/70) / (30/40) = <strong>(20 &times; 40) / (70 &times; 30)</strong> = 0.38</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></blockquote><p>In this case, the OR calculated was the OR of disease (among exposed individuals relative to nonexposed individuals), given by (a/b) / (c/d); in some cases, the OR of exposure (among diseased individuals relative to nondiseased individuals) is calculated, given by (a/c) / (b/d).&nbsp; Both OR definitions are mathematically equivalent and reduce (by a <a href=\"1856\">mathematical shortcut</a>) to: OR = ad/bc.&nbsp; Any of these formulas would give the same result.</p><p>Because the OR is &lt;1, the odds of developing a major arrhythmia is lower for patients who were taking beta blockers compared with those who were not.</p><p><strong>(Choice E)</strong>&nbsp; Relative risk (RR) is the probability of an outcome occurring in the exposed group compared with the probability of the outcome occurring in the unexposed group.&nbsp; It is calculated using the following formula:</p><blockquote><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td align=\"center\">RR = [a/(a + b)] / [c/(c + d)] = (20/90) / (30/70)</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></blockquote><p>RR often has more clinical utility than the OR since it gives the change in disease risk based on the presence or absence of risk factors.&nbsp; However, RR cannot be calculated in case-control studies as patients are preselected based on disease status (cases and controls) instead of being sorted into exposure groups and followed over time to assess disease outcomes.</p><p><strong>Educational objective:</strong><br>The odds ratio (OR) is a measure of the strength of an association between an exposure and an outcome.&nbsp; Specifically, it represents the odds that an outcome occurred in the presence of a particular exposure compared with the odds that the outcome occurred in the absence of that exposure.&nbsp; In a standard contingency table, OR = ad/bc.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1205",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A prospective cohort study was conducted to assess the role of daily alcohol consumption in the occurrence of breast carcinoma.&nbsp; The investigators reported a 5-year relative risk of 1.4 for people who consume alcohol daily compared to those who do not.&nbsp; The 95% confidence interval was 1.02-1.85.&nbsp; Which of the following p-values is most consistent with the results described above?</p>",
      "choices": [
        {
          "id": 1,
          "text": "0.03"
        },
        {
          "id": 2,
          "text": "0.06"
        },
        {
          "id": 3,
          "text": "0.09"
        },
        {
          "id": 4,
          "text": "0.11"
        },
        {
          "id": 5,
          "text": "0.20"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > P-value and confidence interval</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>Relative risk (RR) is used in cohort studies to determine how strongly a risk factor (ie, exposure) is associated with an outcome.&nbsp; RR is the risk of an outcome (eg, breast cancer) in the exposed group (eg, individuals who consume alcohol daily) divided by the risk of that outcome in the unexposed group (eg, individuals who do not consume alcohol daily).&nbsp; If the RR = 1.0 (null value), then there is no association between the exposure and the disease.&nbsp; An RR &gt;1.0 indicates that the exposure is associated with increased risk of disease.&nbsp; An RR &lt;1.0 means that the exposure is associated with decreased risk of disease.</p><p>The RR by itself does not account for the possibility that chance alone is responsible for the results.&nbsp; The 95% confidence interval (CI) and p-value are 2 measures of <strong>statistical significance</strong> that can help strengthen the findings of a study using RR.&nbsp; For a result to be considered statistically significant, its corresponding CI must NOT contain the null value.&nbsp; When the <strong>95% CI</strong> does <strong>not</strong> include the null value, this gives a corresponding <strong>p-value &lt;0.05</strong> and the association between exposure and outcome is considered statistically significant.&nbsp; A p-value &lt;0.05 reflects that there is a very low probability that the result was due to chance alone; formally, the p-value is the probability of observing a given (or more extreme) result due to chance alone assuming that the null hypothesis is true.</p><p>In this example, the RR is 1.4 with a 95% CI of 1.02-1.85.&nbsp; It can be concluded that daily alcohol consumption is associated with an increased risk of breast carcinoma (RR &gt;1) and that the findings are statistically significant (95% CI does not include the null value of 1.0).&nbsp; Therefore, the expected p-value would be &lt;0.05.</p><p><strong>(Choices B, C, D, and E)</strong>&nbsp; These options contain p-values &gt;0.05, so the results would not be statistically significant.&nbsp; Note <a href=\"1855\">the relationship between CI and p-value</a>: a statistically significant 95% CI corresponds to a p-value &lt;0.05; a statistically significant 99% CI (would also not include the null value and likely be wider than a 95% CI) corresponds to a p-value &lt;0.01.</p><p><strong>Educational objective:</strong><br>A result is considered statistically significant if the 95% confidence interval does not cross the null value, which corresponds to a p-value &lt;0.05.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1274",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A researcher studying physician behavior is interested in how often primary care physicians take the sexual histories of patients during clinic visits.&nbsp; As part of the study, patients who attend a primary care clinic are asked to fill out a questionnaire immediately following a visit with their physician.&nbsp; Once the physicians become aware that their own behavior is being studied, which of the following is most likely to be a potential problem?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Berkson&#39;s bias"
        },
        {
          "id": 2,
          "text": "Hawthorne effect"
        },
        {
          "id": 3,
          "text": "Lead-time bias"
        },
        {
          "id": 4,
          "text": "Pygmalion effect"
        },
        {
          "id": 5,
          "text": "Recall bias"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Bias</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>The <strong>Hawthorne effect (observer effect)</strong> is the tendency of study subjects to change their behavior as a result of their awareness that they are being studied.&nbsp; This can impact the observed outcomes, thereby seriously affecting the validity of the study.&nbsp; The Hawthorne effect is commonly seen in studies concerning behavioral outcomes or outcomes that can be influenced by behavioral changes.&nbsp; In this example, physicians (not patients) are the subjects of the study; those physicians who are aware that they are being studied may modify their behavior and start taking sexual histories.&nbsp; To minimize the Hawthorne effect, study subjects can be kept unaware that they are being studied, but this can occasionally pose ethical problems.</p><p><strong>(Choice A)</strong>&nbsp; Berkson&#39;s bias refers to selection bias created by choosing hospitalized patients as the control group.</p><p><strong>(Choice C)</strong>&nbsp; Lead-time bias refers to the apparent prolongation of survival after applying a screening test that detects a disease earlier than it would have been otherwise detected but without any real effect on prognosis.</p><p><strong>(Choice D)</strong>&nbsp; Pygmalion effect describes the fact that a researcher&#39;s beliefs in the efficacy of treatment can potentially affect the outcome.&nbsp; In the classic classroom experiment that first described the Pygmalion effect, a group of students were randomly assigned high intelligence quotient (IQ) scores; their teachers were then told of these artificial results and had higher expectations of this group as a result.&nbsp; The students with the randomly assigned high IQ scores actually performed better, likely because their teachers unconsciously behaved in a manner that would facilitate their success.</p><p><strong>(Choice E)</strong>&nbsp; Recall bias results from inaccurate recall of past exposures by patients.&nbsp; Although recall bias is possible whenever questionnaires are administered, it is unlikely in this case as the patients fill out a form immediately upon leaving the doctor&#39;s office.</p><p><strong>Educational objective:</strong><br>The Hawthorne effect (observer effect) is the tendency of study subjects to change their behavior as a result of their awareness that they are being studied.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1302",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 62-year-old man with diabetes, hypertension, and hyperlipidemia comes to the emergency department of an academic medical center with chest pain, nausea, vomiting, and diaphoresis.&nbsp; An electrocardiogram demonstrates ST elevation in the anterior leads, and cardiac enzymes are markedly elevated.&nbsp; Investigators at the center are designing a randomized control trial to test the hypothesis that drug B will decrease the mortality associated with acute ST-elevation myocardial infarction compared to standard of care.&nbsp; To ensure that investigators will not miss a difference between drug B and standard of care (if a difference truly exists), which of the following would they want to maximize?</p>",
      "choices": [
        {
          "id": 1,
          "text": "&#945;"
        },
        {
          "id": 2,
          "text": "&#946;"
        },
        {
          "id": 3,
          "text": "Type I error"
        },
        {
          "id": 4,
          "text": "Type II error"
        },
        {
          "id": 5,
          "text": "1 &ndash; &#946;"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Power and sample size</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>Statistical <strong>power</strong>, (1 &ndash; &#946;), represents a study&#39;s ability to detect a difference when one exists.&nbsp; It is the probability of rejecting the null hypothesis when it is truly false - ie, the probability of finding a true relationship.&nbsp; Power depends on sample size and the difference in outcome between the groups being tested.&nbsp; In this study, the researchers want to detect a difference between drug B and standard of care if one exists; they want to maximize power.</p><p>&#946; is the probability of committing a type II error <strong>(Choices B and D)</strong>.&nbsp; Type II error occurs when researchers fail to reject the null hypothesis when it is truly false.&nbsp; This causes investigators to miss true relationships.&nbsp; An example of a type II error would be a study finding that aspirin does not affect platelet function when, in fact, it does.&nbsp; Therefore, if &#946; is set at 0.2, the power will be (1 &ndash; &#946;) = 80%; there will be an 80% chance of rejecting the null hypothesis when it is truly false.</p><p><strong>(Choices A and C)</strong>&nbsp; Type I error occurs when researchers reject the null hypothesis when the null hypothesis is really true.&nbsp; That is, a study finds a statistically significant difference between 2 groups when one does not truly exist.&nbsp; An example would be if a study concluded that candy improves heart failure mortality when, in fact, it does not.&nbsp; &#945; is the maximum probability of making a type I error that a researcher is willing to accept.&nbsp; Generally, &#945; is compared to the p-value, the probability of observing a given result (or more extreme) due to chance alone assuming the null hypothesis is true (eg, if there is no real difference between the groups).&nbsp; The value of &#945; is typically set at 0.05, meaning that researchers are willing to accept up to a 5% chance of making a type I error.&nbsp; In such a scenario, if p &lt;0.05, the result is said to be statistically significant.</p><p><strong>Educational objective:</strong><br>Power (1 &#8722; &#946;) is the probability of rejecting a null hypothesis when it is truly false.&nbsp; It is typically set at 80% and depends on sample size and difference between outcomes.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1272",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A researcher is interested in studying whether there is an association between neural tube defects and use of acetaminophen during the first 3 months of pregnancy.&nbsp; He randomly chooses a group of women who have just delivered babies with neural tube defects, and a second group of women who delivered apparently healthy babies.&nbsp; These 2 groups were then asked about their use of acetaminophen during the first 3 months of pregnancy.&nbsp; Which of the following measures of association are the investigators most likely to report?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Median survival"
        },
        {
          "id": 2,
          "text": "Odds ratio"
        },
        {
          "id": 3,
          "text": "Prevalence ratio"
        },
        {
          "id": 4,
          "text": "Relative rate"
        },
        {
          "id": 5,
          "text": "Relative risk"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Odds ratio</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This scenario describes a typical <a href=\"6804\">case-control study design</a>.&nbsp; People with the disease of interest (ie, <strong>cases</strong> [women who have just delivered babies with neural tube defects]) and people without this disease (ie, <strong>controls</strong> [women who delivered apparently healthy babies]) are asked about <strong>previous exposure</strong> to the risk factor being studied (eg, acetaminophen use during the first 3 months of pregnancy).&nbsp; The main measure of association is the <strong>odds ratio (OR)</strong>.&nbsp; The OR can be calculated as follows:</p><p align=\"center\"><strong>OR</strong> = (odds of exposure in cases) / (odds of exposure in controls)</p><p><strong>(Choice A)</strong>&nbsp; Median survival is calculated in cohort studies or clinical trials, and is usually used to compare the median survival times in <u>&gt;</u>2 groups of patients (eg, those receiving a new treatment and those receiving a placebo).</p><p><strong>(Choice C)</strong>&nbsp; Prevalence ratio is a ratio of 2 probabilities (ie, prevalence) commonly used in cross-sectional studies to compare the prevalence of disease among exposed and unexposed groups of people.&nbsp; In case-control studies, cases and controls are selected from a pool of potential cases and controls that do not represent the real frequency (ie, prevalence) of disease in the population.&nbsp; Therefore, estimating the prevalence of disease in case-control studies would be biased.</p><p><strong>(Choices D and E)</strong>&nbsp; Incidence measures (eg, relative risk or relative rate) cannot be directly measured in case-control studies because cases, by definition, already have the disease (ie, the study does not follow a cohort for development of a disease).&nbsp; Relative risk and relative rate are calculated in prospective and retrospective cohort studies, where risk factor assessment occurs <em>first</em> and then exposed and unexposed groups are followed over time and assessed for development of disease.</p><p><strong>Educational objective:</strong><br>A case-control study is used to compare the exposure status of people with the disease (ie, cases) to the exposure status of people without the disease (ie, controls).&nbsp; The main measure of association is the odds ratio.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1277",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A large, multi-country study is conducted to determine the effect of economic development on cancer incidence and mortality.&nbsp; The study uses data obtained from the national cancer registries, along with information regarding per capita gross domestic product as reported by the International Monetary Fund and life expectancy as reported by the World Health Organization.&nbsp; Which of the following best describes the design of this study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Case-control study"
        },
        {
          "id": 2,
          "text": "Cohort study"
        },
        {
          "id": 3,
          "text": "Cross-sectional survey"
        },
        {
          "id": 4,
          "text": "Ecological study"
        },
        {
          "id": 5,
          "text": "Nested case-control study"
        },
        {
          "id": 6,
          "text": "Qualitative study"
        },
        {
          "id": 7,
          "text": "Randomized controlled trial"
        },
        {
          "id": 8,
          "text": "Systematic review"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This observational study is analyzing <strong>population-level data</strong> to evaluate the association between a potential exposure (eg, low socioeconomic status population) and a given outcome (eg, increased cancer mortality).&nbsp; Using population-level (rather than individual-level) data as a unit of analysis in such a manner is consistent with an <strong>ecological study</strong>.&nbsp; Ecological studies are useful for generating hypotheses but should not be used to draw conclusions regarding individuals within these populations (<strong>ecological fallacy</strong>).</p><p><strong>(Choices A and B)</strong>&nbsp; Case-control and cohort studies deal with <em>individuals </em>rather than populations.&nbsp; In case-control studies, the odds of exposure to a certain characteristic (eg, personal socioeconomic status) are compared between affected individuals (eg, patients with cancer) and unaffected individuals who serve as controls.&nbsp; In cohort studies, individuals with and without different exposures (eg, high or low personal socioeconomic status) are followed over time to determine the incidence of the disease of interest (eg, cancer).</p><p><strong>(Choice C)</strong>&nbsp; Cross-sectional surveys evaluate the exposures and outcomes of interest in individuals (not populations) at a given point in time (&#x22;snapshot&#x22;).&nbsp; The overall design of this multi-country study relies on population-level data, not individual-level data.</p><p><strong>(Choice E)</strong>&nbsp; Nested case-control studies start with cohort studies in which participants are followed over time; those participants who develop an outcome of interest become cases for a case-control study.</p><p><strong>(Choice F)</strong>&nbsp; Qualitative studies use focus groups, interviews (structured and semi-structured), and other anthropologic techniques to obtain narrative information for explaining quantitative results.</p><p><strong>(Choice G)</strong>&nbsp; Randomized controlled trials randomly assign subjects into a treatment group or a control group.&nbsp; The groups differ only in the intervention (treatment) of interest.</p><p><strong>(Choice H)</strong>&nbsp; Systematic reviews and meta-analyses combine the results of several published studies (with an emphasis on high-quality, randomized controlled studies) to estimate the pooled effect.</p><p><strong>Educational objective:</strong><br>The unit of analysis in ecological studies is populations rather than individuals.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "9922",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A physician research group is evaluating the efficacy of a new lipid-lowering drug, Superstatin, which is being marketed directly to consumers as a groundbreaking new therapy to prevent heart attacks.&nbsp; The drug manufacturer claims that the drug is more effective than existing hypolipidemic agents for primary prevention of myocardial infarction.&nbsp; Results of a 5-year, randomized, double-blinded, controlled study to evaluate the efficacy of Superstatin are shown below.</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr align=\"center\"><td></td><td>Number of patients treated with Superstatin</td><td>Number of patients treated with control medication</td></tr><tr><td>Myocardial infarction</td><td align=\"center\">10</td><td align=\"center\">25</td></tr><tr><td>No myocardial infarction</td><td align=\"center\">990</td><td align=\"center\">975</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Compared to the control medication, how many patients need to be treated with Superstatin to prevent one additional myocardial infarction?</p>",
      "choices": [
        {
          "id": 1,
          "text": "2"
        },
        {
          "id": 2,
          "text": "5"
        },
        {
          "id": 3,
          "text": "23"
        },
        {
          "id": 4,
          "text": "48"
        },
        {
          "id": 5,
          "text": "67"
        },
        {
          "id": 6,
          "text": "92"
        },
        {
          "id": 7,
          "text": "100"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Number Needed To Treat</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t34642\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"3\"><p align=\"center\"><strong>Common measures of therapeutic efficacy</strong></p></td></tr><tr><td><p align=\"center\"><strong>Term</strong></p></td><td><p align=\"center\"><strong>Definition</strong></p></td><td><p align=\"center\"><strong>Calculation</strong></p></td></tr><tr><td><p align=\"center\"><strong>Absolute risk reduction (ARR)</strong></p></td><td><p>Percentage indicating the actual difference in event rate between control &amp; treatment groups</p></td><td><p align=\"center\">ARR = control rate &ndash; treatment rate</p></td></tr><tr><td><p align=\"center\"><strong>Relative risk reduction (RRR)</strong></p></td><td><p>Percentage indicating relative reduction in the treatment event rate compared to the control group</p></td><td><p align=\"center\">RRR = ARR / control rate</p></td></tr><tr><td><p align=\"center\"><strong>Relative risk (RR)</strong></p></td><td><p>Ratio of the probability of an event occurring in the treatment group compared to the control group</p></td><td><p align=\"center\">RR = treatment rate / control rate</p></td></tr><tr><td><p align=\"center\"><strong>Number needed to treat (NNT)</strong></p></td><td><p>Number of individuals who need to be treated to prevent a negative outcome in 1 patient</p></td><td><p align=\"center\">NNT = 1 / ARR</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>The <strong>number needed to treat (NNT)</strong>&nbsp;represents the number of patients that need to be treated with a medication (eg, Superstatin) in order to <strong>prevent</strong> an additional <strong>negative outcome</strong>&nbsp;(eg, myocardial infarction).&nbsp; NNT is calculated by dividing 1 by the <strong>absolute risk reduction</strong>&nbsp;(ARR).</p><p align=\"center\">NNT = 1 / ARR</p><p>ARR represents the actual difference in control and experimental group event rates.&nbsp; The data is <em>not</em> presented in the standard format of a <a href=\"1811\">contingency (2 &times; 2) table</a>, so care should be exercised in selecting the appropriate values.&nbsp; In this example, the event of interest is myocardial infarction.&nbsp; There were 25 + 975 = 1,000 patients in the control group; of those, 25 had a myocardial infarction.&nbsp; Similarly, there were 10 + 990 = 1,000 patients in the treatment (ie, Superstatin) group; of those, 10 had a myocardial infarction.&nbsp; Therefore:</p><p align=\"center\"><strong>Control event rate</strong> = 25 / 1,000 = 0.025</p><p align=\"center\"><strong>Experimental event rate</strong> = 10 / 1,000 = 0.01</p><p>ARR can then be calculated:</p><p align=\"center\">ARR = Control event rate &ndash; Experimental event rate = 0.025 &ndash; 0.01 = 0.015, or 1.5%</p><p>Finally, NNT is found by dividing 1 by 0.015:</p><p align=\"center\">NNT = 1 / 0.015 = 66.6 &#8776; 67</p><p>Rounding up the result to the nearest whole number, <strong>67 patients</strong> need to be treated with Superstatin to prevent an additional myocardial infarction.</p><p>The ideal NNT would be 1, meaning that all patients in the treatment group benefit from the treatment.&nbsp; A <strong>low NNT</strong> implies that a treatment is <strong>more beneficial</strong> because fewer patients need to be treated to prevent an additional negative outcome.&nbsp; For instance, if a third hypolipidemic medication had an NNT of 40, it would be more beneficial than Superstatin, as only 40 patients would need to be treated over a given period to prevent an additional myocardial infarction.</p><p><strong>Educational objective:</strong><br>The number needed to treat (NNT) is the number of patients that need to be treated with a medication to avoid an additional negative outcome.&nbsp; NNT is calculated by dividing 1 by the absolute risk reduction (the difference between the control and experimental group event rates).&nbsp; Lower NNT values represent more beneficial treatments.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1174",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Zeracizumab is an experimental angiogenesis inhibitor targeting vascular endothelial growth factor that is being tested for the treatment of advanced, chemotherapy-naive, non-squamous non-small cell lung cancer (NSCLC).&nbsp; Part of the drug company&#39;s evaluation process is to analyze the 1-year survival after treatment to determine the clinical efficacy of the experimental treatment.&nbsp; The results are given in the table below.</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr align=\"center\"><td></td><td><strong>Zeracizumab-containing<br>regimen</strong>&nbsp;</td><td><strong>Standard chemotherapy</strong></td></tr><tr><td><strong>Alive at 1 year</strong>&nbsp;</td><td align=\"center\">40</td><td align=\"center\">51</td></tr><tr><td><strong>Dead at 1 year</strong></td><td align=\"center\">60</td><td align=\"center\">69</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Which of the following best represents the number needed to harm for the zeracizumab-containing regimen?</p>",
      "choices": [
        {
          "id": 1,
          "text": "2"
        },
        {
          "id": 2,
          "text": "25"
        },
        {
          "id": 3,
          "text": "40"
        },
        {
          "id": 4,
          "text": "72"
        },
        {
          "id": 5,
          "text": "94"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Number Needed To Treat</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>Unfortunately, not all interventions or new treatments end up helping patients.&nbsp; The <strong>number needed to harm (NNH)</strong> represents the number of people who must be treated before 1 additional adverse event occurs.&nbsp; It is calculated in a manner similar to the number needed to treat (NNT) but using the <strong>absolute risk increase</strong> (attributable risk) instead of the absolute risk reduction:</p><p align=\"center\"><strong>NNH = 1 / Absolute risk increase</strong></p><p>To determine the absolute risk increase, first <strong>calculate the</strong>&nbsp;<strong>adverse event rate</strong> (eg, death) in the experimental and control groups.&nbsp; In this case, the adverse event of interest is death at 1 year.&nbsp; There were 40 + 60 = 100 people treated with the experimental treatment (ie, zeracizumab-containing regimen); of those, 60 were dead at 1 year.&nbsp; Similarly, there were 51 + 69 = 120 people treated with standard chemotherapy; of those, 69 were dead at 1 year.&nbsp; Therefore:</p><p align=\"center\">Adverse event rate in experimental group = 60 / 100 = 0.60 (ie, 60%)<br>Adverse event rate in control group = 69 / 120 = 0.575 (ie, 57.5%)</p><p>The absolute risk increase can then be calculated by <strong>subtracting</strong> the adverse event rate in the control group from the adverse event rate in the treatment group:</p><p align=\"center\">Absolute risk increase = 0.60 &ndash; 0.575 = 0.025 (ie, 2.5%)</p><p>The absolute risk increase attributable to the treatment is <strong>2.5%</strong> (60% risk of being dead at 1 year in the treatment group compared to 57.5% in the control group).&nbsp; The NNH then is simply the <strong>inverse</strong> of the absolute risk increase:</p><p align=\"center\">NNH = 1 / 0.025 = 40</p><p>This result indicates that, on average, <strong>40 patients need to be treated</strong> with a zeracizumab-containing regimen for 1 additional person to experience an adverse event (ie, death in 1 year).</p><p>Note that the data is NOT presented in the standard format of a contingency (2 &times; 2) table, so care should be exercised in selecting the appropriate values and applying the formulas (see <a href=\"10530\">alternate solution</a>).</p><p><strong>Educational objective:</strong><br>The number needed to harm (NNH) represents the number of people who must be treated before 1 additional adverse event occurs.&nbsp; In order to calculate NNH, the absolute risk increase between the treatment and control groups must be known: NNH = 1 / Absolute risk increase</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1231",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A large cohort study is conducted to assess the association between smoking and squamous cell carcinoma of the esophagus among middle-aged Chinese men.&nbsp; During 10 years of follow-up, smokers have 5 times the risk of esophageal carcinoma compared to non-smokers (relative risk = 5.0, 95% confidence interval = 2.9-7.1).&nbsp; According to the study results, what percentage of squamous cell carcinoma of the esophagus in smokers can be attributed to smoking?</p>",
      "choices": [
        {
          "id": 1,
          "text": "25%"
        },
        {
          "id": 2,
          "text": "50%"
        },
        {
          "id": 3,
          "text": "70%"
        },
        {
          "id": 4,
          "text": "80%"
        },
        {
          "id": 5,
          "text": "90%"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Risk</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>The <strong>attributable risk percent in the exposed (ARP<font size=\"2\"><sub>exposed</sub></font>)</strong> is an important measure of the impact of a risk factor.&nbsp; ARP<font size=\"2\"><sub>exposed</sub></font> represents the excess risk in an exposed population that can be explained by exposure to a particular risk factor.&nbsp; It is calculated using the following formula:</p><blockquote><strong>ARP<font size=\"2\"><sub>exposed</sub></font> = 100 &times; [(risk in exposed &ndash; risk in unexposed)/risk in exposed]</strong></blockquote><p>This basic definition can be used to derive an equivalent formula involving relative risk (RR):</p><blockquote><strong>ARP<font size=\"2\"><sub>exposed</sub></font> = 100 &times; [(RR &ndash; 1)/RR]</strong>, where RR = risk in exposed/risk in unexposed</blockquote><p>Applying the formula to this example:</p><blockquote>ARP<font size=\"2\"><sub>exposed</sub></font> = 100 &times; [(RR &ndash; 1)/RR] = 100 &times; [(5 &ndash; 1)/5] = 100 &times; (4/5) = 100 &times; 0.8 = 80%</blockquote><p>Therefore, according to the study results, 80% of esophageal squamous cell carcinoma cases in smokers were attributable to smoking.</p><p>The ARP<font size=\"2\"><sub>exposed</sub></font> is related to the attributable risk (AR), which is simply the difference between risk in the exposed and risk in the unexposed.</p><p><strong>Educational objective:</strong><br>The attributable risk percent (ARP) in the exposed represents the excess risk in the exposed population that can be attributed to the risk factor.&nbsp; It can be easily derived from the relative risk (RR) using the formula: ARP<font size=\"2\"><sub>exposed</sub></font> = 100 &times; [(RR &ndash; 1)/RR].</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1186",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study is designed to evaluate the efficacy of a new drug, KM28.&nbsp; The study will compare KM28 plus standard care versus standard care alone with regard to decreasing the incidence of recurrent breast cancer.&nbsp; The Food and Drug Administration (FDA) will approve the new drug if KM28 plus standard care decreases the rate of breast cancer recurrence by at least 40% compared to standard therapy alone.&nbsp; The recurrence rate on standard therapy is found to be 8%.&nbsp; In order for the FDA to approve KM28, what is the maximal incidence of recurrent disease acceptable for women treated with KM28 plus standard therapy?</p>",
      "choices": [
        {
          "id": 1,
          "text": "2.8%"
        },
        {
          "id": 2,
          "text": "3.2%"
        },
        {
          "id": 3,
          "text": "3.6%"
        },
        {
          "id": 4,
          "text": "4.8%"
        },
        {
          "id": 5,
          "text": "5.2%"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Risk</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>The new drug, KM28, will be approved if its associated recurrence rate is decreased by at least 40% compared to the recurrence rate on standard therapy alone, which is given as 8%.&nbsp; As 40% of 8% is 0.40 &times; 8% = 3.2%, the maximum acceptable recurrence rate is 8% &#8722; 3.2% = 4.8%.&nbsp; Another quick solution would be to state that the maximum acceptable recurrence rate is 60% of 8%, which is 0.60 &times; 8% = 4.8%.</p><p>An alternate solution involves using relative and absolute risk calculations.&nbsp; The 40% (ie, 0.4) mentioned in the prompt refers to <strong>relative risk reduction</strong> (RRR), defined as the percent reduction in absolute risk (AR) between the treatment group (eg, KM28 + standard therapy) and the control group (eg, standard therapy).&nbsp; The formula for RRR is:</p><blockquote>RRR = (AR<font size=\"2\"><sub>control</sub></font> &#8722; AR<font size=\"2\"><sub>treatment</sub></font>) / AR<font size=\"2\"><sub>control</sub></font></blockquote><p>In this example, AR<font size=\"2\"><sub>control</sub></font>, which represents the risk of recurrence with standard therapy, is given as 8% or 0.08.&nbsp; The formula can be rearranged to calculate AR<font size=\"2\"><sub>treatment</sub></font>:</p><blockquote>AR<font size=\"2\"><sub>treatment</sub></font> = AR<font size=\"2\"><sub>control</sub></font> &ndash; (RRR &times; AR<font size=\"2\"><sub>control</sub></font>)</blockquote><p>Plugging in the values for RRR and AR<font size=\"2\"><sub>control</sub></font> gives:</p><blockquote>AR<font size=\"2\"><sub>treatment</sub></font> = 0.08 &ndash; (0.4 &times; 0.08) = 0.08 &ndash; 0.032 = 0.048 (ie, 4.8%)</blockquote><p>RRR may overstate the effectiveness of an intervention.&nbsp; For example, a RRR of 50% occurs whether a drug decreases the incidence of a disease from 2% to 1% or from 50% to 25%.&nbsp; Clearly, the latter is of greater clinical significance.</p><p><strong>Educational objective:</strong><br>Relative risk reduction = (absolute risk<font size=\"2\"><sub>control</sub></font> &#8722; absolute risk<font size=\"2\"><sub>treatment</sub></font>) / absolute risk<font size=\"2\"><sub>control</sub></font></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1176",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A group of researchers conduct a study to evaluate the pharmacologic properties of oxfendazole, an anthelminthic agent.&nbsp; As part of the study, increasing oral doses of oxfendazole (0.5 to 60 mg/kg) are administered to healthy volunteers.&nbsp; Data is collected to form a pharmacokinetic profile of the drug and its metabolites, and the incidence of adverse effects is recorded for the various dosages.&nbsp; A total of 20 healthy male and female (nonchildbearing potential) volunteers participate in the study.&nbsp; Oxfendazole is found to be well tolerated throughout the dose range without any serious adverse effects or deaths.&nbsp; Which of the following best describes this type of study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Preclinical study"
        },
        {
          "id": 2,
          "text": "Phase I clinical trial"
        },
        {
          "id": 3,
          "text": "Phase II clinical trial"
        },
        {
          "id": 4,
          "text": "Phase III clinical trial"
        },
        {
          "id": 5,
          "text": "Phase IV clinical trial"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Clinical trials</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>The <strong>clinical trials process</strong> addresses whether <strong>new treatments</strong> (eg, drugs, procedures) are <strong>effective and safe</strong> for their <strong>intended use</strong> (ie, treatment of a disease) in the <strong>target population</strong> (eg, subjects with the disease of interest).&nbsp; New treatments go through several research phases; some phases involve no human subjects (ie, preclinical studies) and some involve few (ie, phase I and II trials) or many (ie, phase III and IV trials) human subjects.&nbsp; Each of these phases has a different purpose.</p><p>A <strong>phase I trial</strong> is the first step in testing a new treatment in <strong>humans</strong>.&nbsp; Data is collected on the drug&#39;s <strong>pharmacokinetic profile</strong>, metabolism, and pharmacodynamic response (ie, how it affects the body).&nbsp; Different treatment routes (eg, orally, intravenously) may also be investigated.&nbsp; Human safety is assessed in terms of <strong>adverse effects</strong> and the maximum tolerated dose (MTD).&nbsp; <strong>Gradually increasing doses</strong> are typically administered to find the highest dose (ie, MTD) that does not cause unacceptable toxicity.&nbsp; Phase I trials usually include only a <strong>small number</strong> of <strong>healthy subjects</strong>.</p><p><em>Note:&nbsp; Cancer-related phase I trials may involve subjects with cancer (rather than healthy subjects) who have been unresponsive to other treatments. </em></p><p><strong>(Choice A)</strong>&nbsp; Contrary to phase I, II, III, and IV trials, which include human subjects, preclinical studies do not involve human subjects.</p><p><strong>(Choice C)</strong>&nbsp; A phase II trial assesses treatment efficacy in a small number of affected subjects (ie, those with the disease of interest), rather than in healthy subjects.&nbsp; For example, a phase II study would assess efficacy, optimal dosing, and adverse effects of oxfendazole among subjects with helminth infection.&nbsp; The study above evaluated the safety, pharmacokinetic profile, and metabolism of oxfendazole in a small number of <em>healthy subjects</em>.</p><p><strong>(Choice D)</strong>&nbsp; A phase III trial assesses the safety and effectiveness of a new treatment compared to a standard treatment (or placebo); therefore, it involves &#8805;2 groups of affected subjects.&nbsp; For example, a phase III study would evaluate the effectiveness of oxfendazole compared to placebo among subjects with helminth infection.</p><p><strong>(Choice E)</strong>&nbsp; A phase IV trial studies the adverse effects caused over time by a new treatment after it has been approved and is on the market, as with a study to assess adverse effects related to oxfendazole use not seen in earlier trials.</p><p><strong>Educational objective:</strong><br>A phase I trial assesses the pharmacokinetics, pharmacodynamics, and safety profile (eg, adverse events, toxicity) of a new treatment in humans.&nbsp; It is usually conducted on a small number of healthy subjects.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17928",
      "difficulty": "N/A"
    },
    {
      "text": "<p>As part of the Food and Drug Administration drug approval process, a study is conducted to assess the clinical benefit and toxicity of a new drug that is intended to be used in combination with current standard chemotherapy for patients with recurrent glioblastoma.&nbsp; Fifty patients with recurrent glioblastoma enroll in the trial and are randomized to receive standard chemotherapy plus either placebo or 1 of 3 possible doses of the new drug.&nbsp; Study results show a dose-dependent reduction in tumor size with all 3 doses of the new drug, along with a significant increase in adverse drug effects, including hypertension, muscle weakness, lymphopenia, and hypophosphatemia.&nbsp; The researchers conclude that the middle dose of the new drug offers the greatest ratio of benefit to toxicity.&nbsp; Which of the following best describes this type of study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Phase I clinical trial"
        },
        {
          "id": 2,
          "text": "Phase II clinical trial"
        },
        {
          "id": 3,
          "text": "Phase III clinical trial"
        },
        {
          "id": 4,
          "text": "Phase IV clinical trial"
        },
        {
          "id": 5,
          "text": "Preclinical study"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Clinical trials</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img  draggable=\"false\" id=\"55399\" src=\"https://www.uworld.com/media/highresdefault/L67113.jpg\"  ></p><p>Efficacy and safety of new drugs are established during the <strong>clinical trials process</strong>.&nbsp; New drugs are approved by a regulatory body (eg, Food and Drug Administration) following review of phase I to III trials.&nbsp; Phases differ in size, objective, and participant selection.</p><ul><li><p><strong>Phase I:</strong>&nbsp; small trials usually conducted with <strong>healthy participants</strong> to assess safety and pharmacokinetics, often performed in a strictly controlled environment with extensive biochemical and physiologic monitoring.&nbsp; Although some phase I chemotherapy trials may involve subjects with cancer due to the inherent toxicity of treatment, drug efficacy (eg, tumor size reduction) is not assessed during a phase I trial <strong>(Choice A)</strong>.</p></li><li><p><strong>Phase II:</strong>&nbsp; small- to medium-sized trials conducted with participants having the condition of interest to assess <strong>treatment efficacy</strong>, toxicity, <strong>adverse effects</strong>, and <strong>optimal dosing</strong> strategies.&nbsp; These studies may or may not have a control group and can be called pilot studies.</p></li><li><p><strong>Phase III:</strong>&nbsp; <strong>large trials</strong>&nbsp;(typically &gt;300 patients) that are adequately powered to fully assess treatment response and safety, often including analysis of treatment effects in selected subsets of the target patient population.&nbsp; These trials must show adequate effectiveness and safety compared to standard treatment for the drug to obtain <strong>regulatory approval</strong>.</p></li></ul><p><strong>(Choice C)</strong>&nbsp; This trial enrolled a small number of participants with recurrent glioblastoma and compared multiple drug doses with respect to treatment efficacy and toxicity.&nbsp; The results were reported to advise optimal drug dosing (ie, dose-finding); although drug dose correlated with a decrease in tumor size, effectiveness and safety outcomes were not compared with the standard treatment (eg, absolute/relative risks).&nbsp; Therefore, this study is best characterized as a phase II trial.</p><p><strong>(Choice D)</strong>&nbsp; Phase IV trials are performed after a new drug has obtained regulatory approval for clinical use.&nbsp; These trials are typically performed to assess long-term benefits and risks or identify uncommon adverse effects that were not fully characterized in phase III studies.</p><p><strong>(Choice E)</strong>&nbsp; In contrast to phase I, II, III, and IV trials, which include human subjects, preclinical studies do not involve human subjects.</p><p><strong>Educational objective:</strong><br>Phase II studies are small- to medium-sized trials conducted with participants having the condition of interest to assess treatment efficacy, toxicity, adverse effects, and optimal dosing strategies; they are sometimes called pilot studies.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17931",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Researchers conduct a prospective study that demonstrates an association between alcohol consumption and transitional bladder carcinoma, with a relative risk (RR) of 1.81 and a p-value of 0.03.&nbsp; They then divide the study subjects into 2 groups, smokers and non-smokers, and again examine the association between alcohol consumption and bladder cancer:</p><blockquote><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td></td><td>RR</td><td>P-value</td></tr><tr><td>Smokers</td><td>0.95</td><td>0.87</td></tr><tr><td>Non-smokers</td><td>1.03</td><td>0.96</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></blockquote><p>The discrepancy between the overall results and the stratified results is best explained by which of the following?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Confounding"
        },
        {
          "id": 2,
          "text": "Effect modification"
        },
        {
          "id": 3,
          "text": "Measurement bias"
        },
        {
          "id": 4,
          "text": "Meta-analysis"
        },
        {
          "id": 5,
          "text": "Observer bias"
        },
        {
          "id": 6,
          "text": "Recall bias"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Confounding, effect modification, bias, errors</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"1251\"  src=\"https://www.uworld.com/media/L10427.jpg\" draggable=\"false\" ></p><p><strong>Confounding</strong> occurs when the exposure-disease relationship is muddled by the effect of a confounding variable, an extraneous factor associated with both exposure and disease.&nbsp; An example is shown in the <a href=\"1943\">exhibit</a>.&nbsp; In a primary school, it may appear on crude analysis that students with bigger shoe sizes have a higher level of intelligence.&nbsp; However, this association is actually a result of age, not shoe size: Older students tend to have bigger shoe sizes and also to be more intelligent.&nbsp; Age is a confounder because it is associated with both shoe size and intelligence and muddles the association between them.&nbsp; When study subjects are grouped by age (<strong>stratification</strong>), the association between shoe size and intelligence is no longer significant.</p><p>Similarly, initial crude analysis suggested that alcohol use was associated with bladder carcinoma (similar to shoe size being associated with intelligence), with a relative risk (RR) of 1.81 and a p-value &lt;0.05.&nbsp; However, smoking is associated with both bladder carcinoma and alcohol use.&nbsp; Therefore, <strong>smoking</strong> is a potential confounder that may explain the association observed between alcohol use and bladder cancer (similar to age in the school example).&nbsp; Stratified analysis by smoking status shows that both smokers and non-smokers have an RR ~1 with large p-values (&gt;0.05).&nbsp; The RR of 1.81 found on crude analysis disappears and there is no true association between alcohol consumption and bladder cancer.</p><p><strong>(Choice B)</strong>&nbsp; <strong>Effect modification</strong> results when an external variable positively or negatively impacts the observed effect of a risk factor on disease status.&nbsp; When analysis is performed based on stratification by this external variable, there will be a significant difference in risk between the stratified groups.&nbsp; For instance, aspirin use is associated with Reye syndrome in children but not adults; therefore, age modifies the effect of aspirin on Reye syndrome development.&nbsp; Effect modification can easily be confused with confounding; but stratified analysis can help distinguish between them.&nbsp; With confounding, there is usually no significant difference between the strata (as in this case with the smoker and non-smoker strata).</p><p><strong>(Choices C and E)</strong>&nbsp; Measurement bias and observer bias distort the strength of association by misclassifying exposed/unexposed and/or diseased/nondiseased subjects.&nbsp; The scenario does not describe any issues that could affect the classification process.</p><p><strong>(Choice D)</strong>&nbsp; Meta-analysis refers to compiling results from several studies to increase analysis power.</p><p><strong>(Choice F)</strong>&nbsp; Recall bias results from inaccurate recall of past exposure by people in the study and applies mostly to retrospective (eg, case-control) studies.</p><p><strong>Educational objective:</strong><br>Confounding occurs when the exposure-disease relationship is muddled by the effect of an extraneous factor associated with both exposure and disease.&nbsp; Confounding bias can result in the false association of an exposure with a disease.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1173",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A clinical study compares several cut points for a new biomarker for bacterial bloodstream infection among adult patients in the intensive care unit (ICU) against blood culture results.&nbsp; Analysis shows that a biomarker value &#8805;2.6 ng/mL has a sensitivity of 32% and a specificity of 96% for predicting bloodstream infections.&nbsp; Which of the following conclusions about the study results is correct?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Based on a cut point of &#8805;2.6 ng/mL, 4% of adult patients in the ICU with bacterial bloodstream infections will be correctly identified."
        },
        {
          "id": 2,
          "text": "Based on a cut point of &#8805;2.6 ng/mL, 4% of adult patients in the ICU without bacterial bloodstream infections will be incorrectly identified."
        },
        {
          "id": 3,
          "text": "Based on a cut point of &#8805;2.6 ng/mL, 96% of adult patients in the ICU with bacterial bloodstream infections will be correctly identified."
        },
        {
          "id": 4,
          "text": "Based on a cut point of &#8805;2.6 ng/mL, 96% of adult patients in the ICU without bacterial bloodstream infections will be incorrectly identified."
        },
        {
          "id": 5,
          "text": "Of all adult patients in the ICU with bacterial bloodstream infections, 4% will have a biomarker value &lt;2.6 ng/mL."
        },
        {
          "id": 6,
          "text": "Of all adult patients in the ICU with bacterial bloodstream infections, 96% will have a biomarker value &lt;2.6 ng/mL."
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Sensitivity and specificity</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t32272\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td></td><td><p align=\"center\"><strong>Positive condition</strong></p></td><td><p align=\"center\"><strong>Negative condition</strong></p></td><td></td></tr><tr><td><p align=\"center\"><strong>Positive test result</strong></p></td><td><p align=\"center\">TP</p></td><td><p align=\"center\">FP</p></td><td><p align=\"center\">PPV =<br />TP / (TP + FP)</p></td></tr><tr><td><p align=\"center\"><strong>Negative test result</strong></p></td><td><p align=\"center\">FN</p></td><td><p align=\"center\">TN</p></td><td><p align=\"center\">NPV =<br />TN / (TN + FN)</p></td></tr><tr><td></td><td><p align=\"center\">Sensitivity =</p><p align=\"center\">TP / (TP + FN)</p></td><td><p align=\"center\">Specificity =</p><p align=\"center\">TN / (TN + FP)</p></td><td></td></tr><tr><td colspan=\"4\"><p><strong>FN</strong> = false negative; <strong>FP</strong> = false positive; <strong>NPV</strong> = negative predictive value; <strong>PPV</strong> = positive predictive value; <strong>TN</strong> = true negative; <strong>TP</strong> = true positive.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>Compared to blood culture (the reference standard for diagnosing bacterial bloodstream infection), a biomarker value cut point of &#8805;2.6 ng/mL has a sensitivity of 32% and a <strong>specificity of 96%</strong>.</p><ul><li><p>The <strong>specificity</strong> of the test is the percentage of <strong>healthy individuals</strong> (eg, adult patients in the intensive care unit [ICU] without bacterial bloodstream infection) who are <strong>correctly identified</strong> (ie, negative test result) by the diagnostic test.&nbsp; Its complement (1 &#8722; specificity) is the false-positive rate (eg, percentage of adult patients in the ICU without bacterial bloodstream infection who test positive).</p></li><li><p>The sensitivity of the test is the percentage of diseased individuals (eg, ICU patients with bacterial bloodstream infection) who are correctly identified (ie, positive test result) by the diagnostic test.&nbsp; Its complement (1 &#8722; sensitivity) is the false-negative rate (eg, percentage of adult patients in the ICU with bacterial bloodstream infection who test negative).</p></li></ul><p>This test&#39;s specificity indicates that 96% of adult patients in the ICU without bacterial bloodstream infection will be correctly identified (ie, test negative) based on the biomarker cut point of &#8805;2.6 ng/mL (ie, test result &lt;2.6 ng/mL) <strong>(Choice D)</strong>.&nbsp; Conversely, 100% &#8722; 96% = <strong>4%</strong> of adult patients in the ICU <strong>without </strong>bacterial bloodstream infection will be <strong>incorrectly identified</strong>.</p><p><strong>(Choices A, C, E, and F)</strong>&nbsp; This test&#39;s sensitivity indicates that 32% of adult patients in the ICU with bacterial bloodstream infection will be correctly diagnosed (ie, test positive) based on the biomarker cut point of &#8805;2.6 ng/mL.&nbsp; Conversely, 100% &#8722; 32% = 68% of adult patients in the ICU with bacterial bloodstream infection will be missed (ie, test negative with a result &lt;2.6 ng/mL).</p><p><strong>Educational objective:</strong><br>Sensitivity represents the probability that an individual with disease will have a positive test result.&nbsp; Specificity represents the probability that an individual without disease will have a negative test result.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "23879",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A researcher conducts&nbsp;a study to determine the value of measuring kidney volume with computed tomography (CT) to help diagnose chronic kidney disease and quantify kidney damage.&nbsp; In total, 251 patients are enrolled in the study.&nbsp; Correlation analyses are then conducted to evaluate the relationships between kidney volume as measured on CT scans and both glomerular filtration rate and glycosylated hemoglobin (HbA1c).&nbsp; Initial study results show&nbsp;that lower values of HbA1c tended to relate to higher values of kidney volume, and that the relationship was strong and statistically significant.&nbsp; Based on this information, which of the following statements would best describe the associated correlation coefficient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "It is negative and probably closer to &#8722;1 than to 0"
        },
        {
          "id": 2,
          "text": "It is negative and probably closer to 0 than to &#8722;1"
        },
        {
          "id": 3,
          "text": "It is positive and probably closer to 0 than to 1"
        },
        {
          "id": 4,
          "text": "It is positive and probably closer to 1 than to 0"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Correlation coefficient</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img  draggable=\"false\" id=\"35793\" src=\"https://www.uworld.com/media/highresdefault/L59668.png\"  ></p><p>The <strong>correlation coefficient</strong>&nbsp;<em>r</em> describes the linear relationship between 2 quantitative variables by its direction (negative or positive) and its strength (a value closer to &#8722;1 or 1 indicates a stronger relationship).</p><ul><li><p><em>r</em> &gt; 0&nbsp;(ie, <strong>positive</strong>) indicates a direct relationship, so <strong>both variables increase (or decrease) together</strong>.&nbsp; This means that higher (or lower) values of one variable tend to relate to higher (or lower) values of the other variable.</p></li><li><p><em>r</em> &lt; 0&nbsp;(ie, <strong>negative</strong>) indicates an inverse relationship, so as <strong>one variable increases, the other variable decreases</strong>.&nbsp; This means that higher values of one variable tend to relate to lower values of the other variable, and vice versa.</p></li></ul><p>In this study, lower values of HbA1c tended to relate to higher values of kidney volume.&nbsp; This means that one variable increased as the other variable decreased, so the correlation coefficient must be negative<strong> (Choices C and D)</strong>.&nbsp; Because the relationship was described as <strong>strong</strong>, the correlation coefficient must be <strong>closer to &#8722;1</strong> than to 0<strong> (Choice B)</strong>.</p><p><strong>Educational objective:</strong><br>The correlation coefficient <em>r</em> describes the direction (negative or positive) and the strength (a value closer to &#8722;1 or 1 indicates a stronger relationship) of the linear relationship between 2 quantitative variables.&nbsp; It does not necessarily imply causality.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "23893",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Researchers studying the effects of hormone replacement therapy (HRT) on the risk of myocardial infarction (MI) among postmenopausal women calculate the relative risk (RR) of MI to be 1.30 (p = 0.07) among women who are taking HRT compared to those who are not.&nbsp; The researchers conclude that there is no statistically significant increased risk of MI with HRT (based on a cutoff of &#945; = 0.05).&nbsp; Subsequently, the results of a meta-analysis determine that there actually is an increased risk of MI, with an overall RR = 1.32 (p = 0.03) among postmenopausal women who are taking HRT compared to those who are not.&nbsp; Which of the following was the most likely problem in the first study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Berkson&#39;s bias"
        },
        {
          "id": 2,
          "text": "Placebo effect"
        },
        {
          "id": 3,
          "text": "Poor blinding"
        },
        {
          "id": 4,
          "text": "Researcher expectancy"
        },
        {
          "id": 5,
          "text": "Sample size"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Power and sample size</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"6810\"  src=\"https://www.uworld.com/media/L23287.jpg\" draggable=\"false\" ></p><p>The first study and the meta-analysis (combined results of several studies) had similar outcomes in terms of relative risk (RR); however, they arrived at different conclusions because the p-value reached statistical significance (p &lt;&#945; = 0.05) in the meta-analysis but not in the first study.&nbsp; The most probable reason behind this is that the <strong>larger</strong> meta-analysis reflects the true status (increased risk of myocardial infarction [MI] with hormone replacement therapy [HRT]), whereas the first study result represented a <strong>type II (&#946;) error</strong> (<strong>falsely</strong> concluded there was <strong>no</strong> increased risk of MI with HRT).</p><p>The probability of a type II (&#946;) error is related to how much <strong>power</strong> a study has to detect a difference when a difference actually exists (power = 1 &ndash; &#946;).&nbsp; <strong>Sample size</strong> and power are related in that studies with a larger sample size have greater power to detect differences if these exist.&nbsp; The small sample size of the first study made it underpowered to detect a difference in outcome between patients who were treated with HRT and those who were not.</p><p>The sample size did not change the value of &#945; (typically set at 0.05).&nbsp; However, because the first study was underpowered, the p-value obtained was not statistically significant (p = 0.07 &gt;&#945; = 0.05), leading to a false conclusion of no increased risk of MI with HRT.</p><p><strong>(Choice A)</strong>&nbsp; Berkson&#39;s bias refers to selection bias that can be created by selecting hospitalized patients as the control group.</p><p><strong>(Choice B)</strong>&nbsp; Placebo effect refers to patients&#39; expectations affecting an outcome.&nbsp; However, in this case, the control group is taking neither HRT nor a placebo medication.</p><p><strong>(Choices C and D)</strong>&nbsp; Given that the RR obtained in the first study was similar to the one obtained in the meta-analysis (1.32 versus 1.30), it is unlikely that design flaws (eg, poor blinding, researcher expectancy) were present in the study.</p><p><strong>Educational objective:</strong><br>A study&#39;s power increases as its sample size increases.&nbsp; Therefore, the larger the sample, the greater the ability of a study to detect a difference when one truly exists.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1303",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A research group is studying the correlation between BMI and blood pressure in a random sample of children age 12-16.&nbsp; After collecting data, they conduct&nbsp;a correlation analysis at a 1% significance level.&nbsp; The researchers find that BMI correlates&nbsp;with systolic blood pressure with a coefficient of&nbsp;<em>r</em> = 0.46 (<em>p</em> &lt;0.001) and diastolic blood pressure with a coefficient of&nbsp;<em>r</em> = 0.37 (<em>p</em> &lt;0.001).&nbsp; Which of the following is the most accurate interpretation of these results?</p>",
      "choices": [
        {
          "id": 1,
          "text": "An increase in BMI causes a statistically significant increase in blood pressure in children"
        },
        {
          "id": 2,
          "text": "Childhood obesity significantly increases the risk of cardiovascular disease later in life"
        },
        {
          "id": 3,
          "text": "There is a statistically significant negative linear relationship between BMI and blood pressure in children"
        },
        {
          "id": 4,
          "text": "There is a statistically significant positive linear relationship between BMI and blood pressure in children"
        },
        {
          "id": 5,
          "text": "There is no statistically significant linear relationship between BMI and blood pressure in children"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Correlation coefficient</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"7183\" src=\"https://www.uworld.com/media/L18045.png\" ></p><p>The <strong>correlation coefficient</strong> (<em>r</em>) measures the direction and strength of a <strong>linear relationship</strong> (ie, association) between 2 variables (that are usually quantitative).</p><ul><li><p><strong>Direction:</strong>&nbsp; When <em>r</em> &lt;0, the linear relationship is negative and one variable increases as the other decreases; when <em>r</em> &gt;0, the linear relationship is positive and both variables increase and decrease together.</p></li><li><p><strong>Strength:</strong>&nbsp; When <em>r</em> values are close to &#8722;1 or 1, the linear relationship is strong; when <em>r</em> values are close to 0, the linear relationship is weak.</p></li></ul><p>A <strong>correlation analysis</strong> evaluates whether a <strong>linear relationship exists</strong> between 2 variables.&nbsp; A <em>p</em>-value less than a given significance level indicates that there is a statistically significant linear relationship between the variables.&nbsp; However, a statistically significant linear relationship result does not imply that the relationship is causal (<strong>correlation &#8800; causation</strong>) because when 2 variables are correlated, it does not necessarily mean that one is directly causing the other to change <strong>(Choices A and B)</strong>.</p><p>In this study, researchers studied the correlation between BMI and blood pressure in a random sample of children.&nbsp; Study results showed that the correlation coefficients for BMI and systolic/diastolic blood pressure are both positive (<em>r</em> = 0.46 and <em>r</em> = 0.37, respectively, are both &gt;0); therefore, there is a <strong>positive linear relationship</strong> between BMI and blood pressure <strong>(Choice C)</strong>.&nbsp; Because the <em>p</em>-value for both coefficients (<em>p</em> &lt;0.001) is less than 0.01 (the given significance level of 1%), the linear relationship is&nbsp;<strong>statistically significant (Choice E)</strong>.</p><p><strong>Educational objective:</strong><br>The correlation coefficient (<em>r</em>) indicates whether there is a negative (<em>r</em> &lt;0) or positive (<em>r</em> &gt;0) linear relationship between 2 variables.&nbsp; The closer <em>r</em> is to &#8722;1 or +1, the stronger the linear relationship.&nbsp; A statistically significant (ie, <em>p</em>-value &lt; significance level) linear relationship between 2 variables does not imply that the relationship is causal.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "18166",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study is designed to describe the manifestations of coronavirus disease 2019 (COVID-19) on imaging studies, particularly on computerized tomography (CT) scans.&nbsp; Eleven patients with COVID-19 are recruited for the study, and their CT findings are studied and characterized.&nbsp; Which of the following best describes this study design?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Case-control"
        },
        {
          "id": 2,
          "text": "Case series"
        },
        {
          "id": 3,
          "text": "Clinical trial"
        },
        {
          "id": 4,
          "text": "Cohort"
        },
        {
          "id": 5,
          "text": "Cross-sectional"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Research studies</strong> are broadly classified as having an observational design or an experimental design depending on the control the researchers have over the independent variables.</p><ul><li><p>In <strong>observational studies</strong> (eg, case series, case-control studies, cohort studies, cross-sectional studies), the researchers have <strong>no control</strong> over the independent variables (eg, exposure to risk factors, treatments).</p></li><li><p>In experimental studies (eg, crossover design, randomized controlled trials), the researchers control and randomly assign the independent variables (eg, exposure to risk factors, treatments).</p></li></ul><p><strong>Case series</strong> is a descriptive observational study design in which a (generally small) group of patients with a similar diagnosis or treatment is described at a point in time or followed over a certain time period.&nbsp; Contrary to other observational designs (eg, cohort, case-control), a case series has <strong>no comparison group (Choices A and D)</strong>.&nbsp; For this reason, a case series cannot establish associations between risk factors (eg, treatments) and outcomes (eg, diseases).</p><p>In this example, the CT scan findings of 11 patients with coronavirus disease 2019 (COVID-19) are being studied.&nbsp; The study has no control group; therefore, it can only describe COVID-19 manifestations on imaging studies.</p><p><strong>(Choice C)</strong>&nbsp; A clinical trial is an experimental study in which patients are prospectively assigned to &#8805;2&nbsp;interventions (often including&nbsp;a placebo or control treatment) to evaluate the effects of those interventions on outcomes of interest.</p><p><strong>(Choice E)</strong>&nbsp; A cross-sectional study is an observational study that assesses a population of interest (eg, all women of reproductive age) at a single point in time; it can be used to estimate disease prevalence and association with risk factors of interest.&nbsp; However, it is not used to characterize disease findings because subjects are not selected based on the presence of disease.</p><p><strong>Educational objective:</strong><br>A case series is a descriptive observational study design in which a group of patients with a similar diagnosis or treatment is described at a point in time or followed over a certain period.&nbsp; This study design has no comparison group; therefore, it cannot establish associations between risk factors (eg, treatments) and outcomes (eg, diseases).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17787",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A research group conducted a study to compare the levels of creatine kinase-MB (CK-MB) between type 2 diabetes mellitus (T2DM) patients given statin therapy.&nbsp; Participants were divided into 4 groups based on treatment.&nbsp; Groups I, II, and III consisted of T2DM patients who had been given statin therapy (atorvastatin, simvastatin, rosuvastatin, respectively) for at least 6 months.&nbsp; Group IV consisted of T2DM patients who had not been given statin therapy.&nbsp; Which of the following statistical tests is most appropriate to compare the CK-MB levels between Groups I, II, III, and IV in this study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Analysis of variance"
        },
        {
          "id": 2,
          "text": "Chi-square test"
        },
        {
          "id": 3,
          "text": "Independent t-test"
        },
        {
          "id": 4,
          "text": "Paired t-test"
        },
        {
          "id": 5,
          "text": "Correlation analysis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Statistical tests</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t35860\"><table class=\"table-default-style table-footer-only-style\"><tbody><tr><td></td><td></td><td colspan=\"2\"><p align=\"center\"><strong>Dependent variable</strong></p></td></tr><tr><td></td><td></td><td><p align=\"center\"><em>Qualitative (categorical)</em></p></td><td><p align=\"center\"><em>Quantitative </em></p></td></tr><tr><td rowspan=\"2\"><p align=\"center\"><strong>Independent variable</strong></p></td><td><p align=\"center\"><em>Qualitative (categorical)</em></p></td><td><p align=\"center\">Chi-square, logistic regression*</p></td><td><p align=\"center\"><em>t</em> test, ANOVA, linear regression</p></td></tr><tr><td><p align=\"center\"><em>Quantitative</em></p></td><td><p align=\"center\">Logistic regression*</p></td><td><p align=\"center\">Correlation, linear regression</p></td></tr><tr><td colspan=\"4\"><p>*Dependent variable must be dichotomous.</p><p><strong>ANOVA</strong> = &nbsp;analysis of variance.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>Variables are broadly classified as qualitative (ie, categorical) or quantitative (eg, continuous) based on their scale of measurement.&nbsp; <strong>Qualitative variables</strong> (eg, type of treatment, blood type) represent categories or groups, whereas <strong>quantitative variables</strong> (eg, temperature, glucose levels) represent numerical values, with quantitative variables (eg, temperature) sometimes transformed into qualitative variables (eg, &#x22;no fever&#x22; for &lt;38 C [100 F]; &#x22;fever&#x22; for &#8805;38 C [100 F ]).&nbsp; The scale of measurement of the dependent (eg, outcome) and independent (eg, exposures, risk factors) variables in a study determines the correct statistical test for any given situation.</p><p>The <strong>analysis of variance (ANOVA)</strong> test compares the <strong>means of &#8805;3 groups</strong>.&nbsp; It requires a categorical independent variable (ie, exposure) that is used to divide the study pool into &#8805;3 groups and a quantitative dependent variable (ie, outcome) for which an average (eg, mean) can be calculated.&nbsp; In this study:</p><ul><li><p>The quantitative dependent variable was the <strong>levels of creatine kinase-MB</strong> (CK-MB).</p></li><li><p>The categorical independent variable was type of statin therapy that was used to categorize <strong>4 different groups</strong> of patients with type 2 diabetes mellitus (T2DM): Group I (atorvastatin), Group II (simvastatin), Group III (rosuvastatin), and Group IV (no statin).</p></li></ul><p>An <a href=\"33900\">ANOVA test</a> can determine whether there is a statistically significant difference in mean levels of CK-MB among T2DM patients given different statin therapies.&nbsp; A large, statistically significant difference in mean CK-MB levels among groups indicates that different statin therapies are associated with significant changes in CK-MB levels (ie, the null hypothesis is rejected).</p><p><strong>(Choice B)</strong>&nbsp; The chi-square test evaluates the association between 2 categorical variables, as in a study evaluating the association between sex (ie, &#x22;male&#x22; and &#x22;female&#x22;) and myocardial infarction (ie, presence of myocardial infarction, absence of myocardial infarction).</p><p><strong>(Choices C and D)</strong>&nbsp; The <em>t</em>-tests compare the mean of a quantitative variable <em>between 2 groups</em>.&nbsp; A paired <em>t</em>-test is used when the groups are dependent (eg, comparing mean blood pressure [quantitative variable] in the same group of patients before and after antihypertensive therapy).&nbsp; An independent <em>t</em>-test is used when the groups are independent (eg, comparing mean CK-MB levels [quantitative variable] between a group of patients given statin therapy and another not given statin therapy).</p><p><strong>(Choice E)</strong>&nbsp; A correlation analysis uses the <a href=\"7183\">correlation coefficient</a> to describe the linear relationship between 2 quantitative variables, as in a study evaluating the <a href=\"19814\">linear relationship</a> between hours of sleep and irritability score.</p><p><strong>Educational objective:</strong><br>The analysis of variance test compares the means of &#8805;3 groups.&nbsp; The test requires a categorical independent variable (ie, exposure) that is used to divide the study pool into &#8805;3 groups and a quantitative dependent variable (ie, outcome) for which an average (eg, mean) can be calculated.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17735",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A large prospective study evaluates the relationship between alcohol consumption and breast cancer.&nbsp; A total of 4000 middle-aged women are enrolled in the study through a random selection of residential addresses.&nbsp; Daily alcohol consumption and breast cancer incidence are assessed through the use of periodic questionnaires.&nbsp; On five-year follow-up, the investigators report the association between alcohol consumption and breast cancer as a relative risk of 1.32 (95% confidence interval = 0.90-1.85); 800 subjects were lost to follow-up by the end of the study, the majority of whom were moderate to heavy alcohol consumers.&nbsp; According to this information, which of the following biases is most likely to be present and may have affected the results?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Lead-time bias"
        },
        {
          "id": 2,
          "text": "Observer bias"
        },
        {
          "id": 3,
          "text": "Random misclassification bias"
        },
        {
          "id": 4,
          "text": "Recall bias"
        },
        {
          "id": 5,
          "text": "Selection bias"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Confounding, effect modification, bias, errors</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"6792\" src=\"https://www.uworld.com/media/L13931.jpg\" ></p><p><strong>Bias</strong> refers to a systematic error (due to nonrandom factors) that can result in an incorrect association between the exposure and outcome.&nbsp; In general, when bias is present, the <strong>results are consistently distorted</strong> in one direction.&nbsp; In prospective studies, if <strong>loss to follow-up occurs disproportionately</strong> between the exposed and unexposed groups, <strong>attrition bias</strong> can result if the lost subjects differ in their risk of developing the outcome compared to the remaining subjects.&nbsp; Attrition bias is a<strong> form of selection bias</strong> (a term that most often refers to systematic differences between groups in terms of treatment response or prognosis).&nbsp; Attrition bias does not occur when the losses happen randomly between the exposed and unexposed groups, as this simply leads to a smaller study population.</p><p>In this example, a substantial number of subjects (800 / 4000 = 20%) were lost to follow-up, primarily those with higher levels of alcohol consumption.&nbsp; If these lost subjects had a higher incidence of breast cancer than those remaining in the study, then a selective loss of high-risk subjects would have occurred in the exposed group.&nbsp; As a result, the measure of the association between alcohol use and breast cancer would be underestimated, which might explain why no significant association was seen in this study (as the confidence interval of 0.90 to 1.85 crosses 1, which is the null value for relative risk).</p><p><strong>(Choice A)</strong>&nbsp; Lead-time bias occurs when a screening test diagnoses a disease earlier than it would have appeared by natural history alone, so that the time from diagnosis until death appears prolonged even though there might actually be no improvement in survival.</p><p><strong>(Choice B)</strong>&nbsp; Observer bias can occur in clinical trials when study participants or investigators are aware of individual treatment assignments.&nbsp; It can be prevented by performing a double-blind study in which neither participants nor investigators are aware of treatment assignments.</p><p><strong>(Choice C)</strong>&nbsp; Misclassification bias occurs when either the exposure or the outcome is not identified correctly.&nbsp; Random (or nondifferential) misclassification affects all groups to the same extent.&nbsp; For example, if a pediatric size sphygmomanometer cuff is used on all participants (treatment and control groups) as part of a study in adult patients, the blood pressure readings will be incorrect (due to the incorrect cuff size).&nbsp; However, the resulting misclassification will likely affect both groups to the same extent (because the same cuff was used).</p><p><strong>(Choice D)</strong>&nbsp; Recall bias results from the inaccurate recall of past exposure status.&nbsp; It is a potential problem for retrospective studies such as case-control studies, particularly when questionnaires are used to inquire about distant past exposure.&nbsp; However, in this prospective study, exposure status is determined through periodic questionnaires assessing daily alcohol consumption (without inquiring about distant past exposure).&nbsp; In such a scenario, recall bias is less likely to affect results.</p><p><strong>Educational objective:</strong><br>In prospective studies, disproportionate loss to follow-up between the exposed and unexposed groups creates the potential for attrition bias, which is a form of selection bias.&nbsp; As a result, investigators generally try to achieve high patient follow-up rates in prospective studies.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1188",
      "difficulty": "N/A"
    },
    {
      "text": "<p>An investigator is conducting a randomized, double-blind, placebo-controlled clinical trial of a new drug for the treatment of peripheral neuropathy in adults with multiple myeloma (MM).&nbsp; One hundred fifty patients with MM are enrolled in the trial and randomized to receive either the new drug (<em>n</em> = 75) or placebo (<em>n</em> = 75).&nbsp; Trial protocol requires that patients in both groups take 1 pill per day and keep a pain diary.&nbsp; After 3 months of treatment, each patient is interviewed, and the pain diaries are reviewed; 9 patients taking the new drug and 3 patients taking placebo did not take the pills as instructed.&nbsp; The investigator decides to conduct an intention-to-treat analysis of the study data.&nbsp; Which of the following best describes how the data pertaining to all patients who did not adhere to protocol should be treated?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Conduct separate analyses of the 12 nonadherent patients and the 138 adherent patients"
        },
        {
          "id": 2,
          "text": "Exclude all 12 nonadherent patients from analysis"
        },
        {
          "id": 3,
          "text": "Exclude the 3 nonadherent patients in the group taking placebo from analysis"
        },
        {
          "id": 4,
          "text": "Exclude the 9 nonadherent patients in the group taking the new drug from analysis"
        },
        {
          "id": 5,
          "text": "Keep all 12 nonadherent patients in their respective groups for analysis"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Randomized control trials</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>An <strong>intention-to-treat</strong> (ITT) analysis compares treatment groups in a randomized trial by <strong>including all subjects</strong> as initially allocated after randomization <strong>regardless of what happens</strong> during the study period.&nbsp; The rationale is that if subjects have such a poor treatment response (or are so inconvenienced by treatment administration or side effects) as to not follow protocol specifications or drop out of the study, then their outcomes should be attributed to that intervention (ie, nonadherence is related to the practical benefits of treatment).&nbsp; ITT analysis also helps avoid the effects of attrition (eg, loss to follow-up, dropout) and crossover (eg, switching to another assigned intervention), which may disrupt the benefit of randomization and introduce bias in the estimation of the effect of the intervention.</p><p>ITT analysis may lead to a more <strong>conservative estimate</strong> of the effect of the intervention.&nbsp; If attrition or crossover is significant, ITT analysis may be less likely to identify a statistically significant difference between treatments (ie, shift toward the null hypothesis).&nbsp; However, results will reflect the <strong>expected effect</strong> of the intervention in a <strong>practical clinical setting</strong>.</p><p><strong>(Choices A, C, and D)</strong>&nbsp; In accordance with ITT analysis, the investigator in this case should keep the 12 nonadherent patients in their respective groups for analysis.</p><p><strong>(Choice B)</strong>&nbsp; An analysis that includes only those patients who strictly adhered to a research protocol (ie, excluding all nonadherent patients from analysis) follows a per-protocol (PP) principle.&nbsp; In PP analysis, the benefit of randomization can be lost with significant subject attrition (eg, sicker subjects selectively dropping out, introducing bias).&nbsp; PP analysis can also overestimate&nbsp;the effect of the intervention in a practical clinical setting, particularly when the treatment is somehow aversive to patients.</p><p><strong>Educational objective:</strong><br>Intention-to-treat analysis includes each subject in their initial randomization group even if subjects stop the intervention or shift to a different intervention.&nbsp; This approach tends to provide a conservative but more valid estimate of the intervention effect in real-world scenarios (ie, clinical settings).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17946",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study is conducted to assess the relationship between smoking status and forced expiratory volume in one second (FEV<font size=\"2\"><sub>1</sub></font>).&nbsp; Subjects are randomly selected and categorized based on smoking status.&nbsp; Group A consists of 200 nonsmokers, group B consists of 200 light smokers (1-7 cigarettes per day), group C consists of 200 moderate smokers (8-22 cigarettes per day), and group D consists of 200 heavy smokers (23+ cigarettes per day).&nbsp; FEV<font size=\"2\"><sub>1</sub></font> is quantitatively measured in all participants using properly calibrated office spirometers.&nbsp; Which of the following is the most appropriate statistical method to compare the mean FEV<font size=\"2\"><sub>1</sub></font> results among all 4 groups?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Analysis of variance"
        },
        {
          "id": 2,
          "text": "Chi-square test"
        },
        {
          "id": 3,
          "text": "Meta-analysis"
        },
        {
          "id": 4,
          "text": "Multiple logistic regression"
        },
        {
          "id": 5,
          "text": "Pearson correlation coefficient"
        },
        {
          "id": 6,
          "text": "Two-sample t-test"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Statistical tests</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"33900\" src=\"https://www.uworld.com/media/L10433.png\" ></p><p><strong>Analysis of variance (ANOVA)</strong> is used to determine whether there are any significant <strong>differences between the means</strong>&nbsp;of <strong>several independent groups</strong>.</p><p>ANOVA compares the means between the groups relative to the variability within groups (F-test) and determines whether any of those means are significantly different from one another.&nbsp; Specifically, it tests the <strong>null hypothesis</strong> that all groups are simply random samples of the same population (ie, the <strong>means are the same</strong>).&nbsp; The null hypothesis is rejected when there are at least 2 group means that are significantly different from one another.</p><p>ANOVA can be used to compare &#8805;2 groups but is generally used to compare <strong>&#8805;3 groups</strong> (because other equivalent methods exist to compare 2 groups).&nbsp; For example, the 2 independent samples <em>t</em>-test is a special case of the F-test in ANOVA.&nbsp; The assumptions for both tests and their resulting <em>p</em>-values are the same.</p><p><strong>(Choice B)</strong>&nbsp; Chi-square tests can be used to evaluate the association between 2 <em>categorical</em> variables.&nbsp; For example, if FEV<font size=\"2\"><sub>1</sub></font> is measured as a categorical variable (eg, normal or low), then a chi-square test could be used to determine if there is an association between FEV<font size=\"2\"><sub>1</sub></font>&nbsp;and smoking status.&nbsp; However, this study is specifically comparing the mean FEV<font size=\"2\"><sub>1</sub></font> results (a <em>quantitative</em> variable) between groups.</p><p><strong>(Choice C)</strong>&nbsp; Meta-analysis involves the pooling of data from several studies to perform an analysis with greater statistical power than the individual studies alone.&nbsp; For example, individual studies assessing the effects of aspirin on certain cardiovascular events may be inconclusive.&nbsp; However, analysis of data compiled from multiple clinical trials may reveal a significant benefit.</p><p><strong>(Choice D)</strong>&nbsp; Multiple logistic regression is a method used to predict the probability of a binary outcome (eg, presence or absence of gastric cancer) based on 1 or more independent variables that can be either continuous or categorical.&nbsp; For example, this test could be used to predict the probability of gastric cancer based on alcohol consumption, tobacco use, and charred food consumption.</p><p><strong>(Choice E)</strong>&nbsp; The Pearson correlation coefficient is a measure of the strength and direction of a linear relationship between 2 quantitative (ie, continuous) variables.&nbsp; For example, a study may report a correlation coefficient describing the association between hemoglobin A1c levels and average blood glucose levels.</p><p><strong>(Choice F)</strong>&nbsp; A two-sample <em>t</em>-test can be used when 2 group means are compared.&nbsp; This test could have been used for the example in the question if the study participants were divided into smoking and nonsmoking groups only (ie, 2 groups instead of 4).</p><p><strong>Educational objective:</strong><br>A <em>t</em>-test is used to compare the difference between the means of 2 groups.&nbsp; Analysis of variance (ANOVA) compares the difference between the means of 2 or more groups.&nbsp; Results from a <em>t</em>-test and ANOVA test will be equivalent when comparing the difference between the means of 2 groups.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "8513",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study is performed to compare the effect of tramadol when compared to placebo for painful polyneuropathy.&nbsp; Fifty patients are selected and randomly allocated to 1 of 2 treatment sequences:&nbsp; Tramadol followed by placebo, or placebo followed by tramadol.&nbsp; The initial treatment period is delivered for 4 weeks followed by an interim 1-week washout phase, after which the second treatment period is delivered for an additional 4 weeks.&nbsp; After each treatment period, patients use a 10-point numeric scale to rate pain, paresthesia, and tenderness.&nbsp; Which of the following best describes this study design?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Case-control study"
        },
        {
          "id": 2,
          "text": "Case series study"
        },
        {
          "id": 3,
          "text": "Crossover study"
        },
        {
          "id": 4,
          "text": "Cross-sectional study"
        },
        {
          "id": 5,
          "text": "Prospective cohort study"
        },
        {
          "id": 6,
          "text": "Retrospective cohort study"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"7793\" src=\"https://www.uworld.com/media/L10067.png\" ></p><p>In this example, patients are allocated to 1 of 2 treatment groups:&nbsp; Group A receives placebo followed by tramadol and Group B receives tramadol followed by placebo.&nbsp; After the initial 4-week treatment period and the 1-week washout phase, the <strong>treatments are switched</strong> and delivered for an additional 4 weeks.&nbsp; This is consistent with a <strong>crossover study</strong>, in which subjects are randomly allocated to a sequence of 2 or more treatments given consecutively.&nbsp; The simplest model is the AB/BA type of study in which half of the subjects are allocated to the AB study arm and receive treatment A followed by treatment B, while the other half of the subjects are allocated to the BA study arm and receive the same treatments but in reverse order.&nbsp; In this way, crossover trials allow the patients to serve as their <strong>own controls</strong>.</p><p>The principal drawback of crossover trials is that the effects of one treatment may <strong>carry over</strong> and alter the response to a subsequent treatment.&nbsp; To avoid this, a <strong>washout phase</strong> (no treatment) is often added between treatments.&nbsp; The washout period is designed to be long enough to allow the effects of prior treatment to wear off.</p><p><strong>(Choice A)</strong>&nbsp; A case-control study is designed by selecting patients with a particular disease (cases) and without that disease (controls), then determining their past exposure status to <u>&gt;</u>1 risk factors believed to be associated with the disease of interest.</p><p><strong>(Choice B)</strong>&nbsp; A case series is a descriptive study that tracks patients with a known condition (eg, a particular exposure, risk factor, or disease) to document the natural history or response to treatment.&nbsp; Unlike a case-control study, a case series is a descriptive study that cannot quantify statistical significance.</p><p><strong>(Choice D)</strong>&nbsp; A cross-sectional study is also known as a prevalence study.&nbsp; It is characterized by the simultaneous measurement of exposure and outcome.&nbsp; It is a snapshot study design that frequently uses surveys.&nbsp; These studies are relatively inexpensive and easy to perform.</p><p><strong>(Choices E and F)</strong>&nbsp; Prospective cohort studies identify 2 groups of individuals (ie, cohorts), based on their exposure status to a risk factor.&nbsp; These 2 cohorts are then followed over time to assess development of the disease of interest.&nbsp; Sometimes the exposure status is determined retrospectively, typically using medical records, and patients are tracked from the point of exposure onward.</p><p><strong>Educational objective:</strong><br>In a crossover study, subjects are randomly allocated to a sequence of 2 or more treatments given consecutively.&nbsp; A washout (no treatment) period is often added between treatment intervals to limit the confounding effects of prior treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "8418",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A case-control study was conducted to estimate the association between simvastatin therapy and serum levels of fibrinogen in patients who underwent percutaneous coronary intervention.&nbsp; Cases were identified as patients who underwent percutaneous coronary intervention and had high periprocedural levels of fibrinogen (&gt;400 mg/dL), and controls were identified as patients who underwent percutaneous coronary interventions but had normal levels of fibrinogen (200-400 mg/dL).&nbsp; History of simvastatin therapy use was assessed through chart review for every patient.&nbsp; The number of patients corresponding to each classification criteria is given in the table below.</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr align=\"center\"><td></td><td>Fibrinogen high (&gt;400 mg/dL)</td><td>Fibrinogen normal (200-400 mg/dL)</td><td>Total</td></tr><tr align=\"center\"><td>Simvastatin therapy</td><td>43</td><td>67</td><td>110</td></tr><tr align=\"center\"><td>No simvastatin therapy</td><td>32</td><td>58</td><td>90</td></tr><tr align=\"center\"><td>Total</td><td>75</td><td>125</td><td>200</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Which of the following is the best statistical method to estimate the association between simvastatin use and high serum fibrinogen levels in this study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Analysis of variance"
        },
        {
          "id": 2,
          "text": "Chi-square test"
        },
        {
          "id": 3,
          "text": "Correlation analysis"
        },
        {
          "id": 4,
          "text": "Meta-analysis"
        },
        {
          "id": 5,
          "text": "Two-sample t-test"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Statistical tests</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t35860\"><table class=\"table-default-style table-footer-only-style\"><tbody><tr><td></td><td></td><td colspan=\"2\"><p align=\"center\"><strong>Dependent variable</strong></p></td></tr><tr><td></td><td></td><td><p align=\"center\"><em>Qualitative (categorical)</em></p></td><td><p align=\"center\"><em>Quantitative </em></p></td></tr><tr><td rowspan=\"2\"><p align=\"center\"><strong>Independent variable</strong></p></td><td><p align=\"center\"><em>Qualitative (categorical)</em></p></td><td><p align=\"center\">Chi-square, logistic regression*</p></td><td><p align=\"center\"><em>t</em> test, ANOVA, linear regression</p></td></tr><tr><td><p align=\"center\"><em>Quantitative</em></p></td><td><p align=\"center\">Logistic regression*</p></td><td><p align=\"center\">Correlation, linear regression</p></td></tr><tr><td colspan=\"4\"><p>*Dependent variable must be dichotomous.</p><p><strong>ANOVA</strong> = &nbsp;analysis of variance.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>Variables can be broadly classified as qualitative (ie, categorical) or quantitative (eg, continuous) based on their scale of measurement.&nbsp; <strong>Qualitative variables</strong> (eg, disease status, blood type) represent <strong>categories or groups</strong>, whereas <strong>quantitative variables</strong> (eg, body weight, glucose levels) represent <strong>numerical values</strong>.&nbsp; Choosing the correct statistical test always depends on the type of dependent and independent variables under consideration.</p><p>The <strong>chi-square test</strong> for independence (also known as chi-square test for association) is used to evaluate the association between <strong>2 categorical variables</strong>.&nbsp; In this example, patients are divided into 2 groups based on serum <strong>fibrinogen levels</strong> (dependent categorical variable: <strong>normal</strong> [200-400 mg/dL],<strong> high</strong> [&gt;400 mg/dL]) and then divided again based on <strong>simvastatin exposure</strong> status (independent categorical variable: <strong>treated</strong>,<strong> not treated</strong>), with the data recorded in a 2 &times; 2 table.&nbsp; A chi-square test may be conducted to determine whether a statistically significant association exists between simvastatin use and the high levels of serum fibrinogen.&nbsp; A large difference in the frequency of simvastatin use between cases and controls is indicative of an association between simvastatin use and high levels of fibrinogen (ie, the null hypothesis is rejected).</p><p><strong>(Choices A and E)</strong>&nbsp; The analysis of variance (ANOVA) and two-sample <em>t</em>-test are used to compare the <em>means</em> between groups.&nbsp; This would require the dependent variable (ie, outcome) to be a <em>quantitative</em> variable.&nbsp; The difference between these 2 tests resides in the number of groups compared.&nbsp; The <em>t</em>-test is used to compare 2 group means, whereas the ANOVA is used to compare &#8805;2 group means.&nbsp; Either of these tests would be appropriate in this example if fibrinogen levels were recorded as a quantitative variable (ie, the actual measured level in mg/dL) instead of a categorical variable (ie, normal or high).</p><p><strong>(Choice C)</strong>&nbsp; The correlation coefficient is a measure of the strength and direction of a linear relationship between 2 <em>quantitative</em> variables.&nbsp; For example, a study may report a correlation coefficient describing the association between hemoglobin A1c levels and average blood glucose levels.</p><p><strong>(Choice D)</strong>&nbsp; Meta-analysis is an epidemiological method of pooling the data from several studies to conduct an analysis having a relatively larger statistical power than that of the individual studies.</p><p><strong>Educational objective:</strong><br>A 2 &times; 2 table is normally used to record the presence or absence of exposure and disease in research.&nbsp; Rows and columns represent the different levels for each categorical (ie, exposure and disease) variable.&nbsp; The chi-square test for independence is used to evaluate the association between 2 categorical variables.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1184",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Researchers want to explore the association between selective serotonin reuptake inhibitor (SSRI) use and pulmonary tuberculosis.&nbsp; A random sample of subjects age 20-84&thinsp;with newly diagnosed pulmonary tuberculosis and an independent random sample of subjects without pulmonary tuberculosis are enrolled in the study.&nbsp; Subsequently, subjects who never had a prescription for an SSRI are defined as &#x22;never users,&#x22; and those who have had a prescription for an SSRI are defined as &#x22;users.&#x22;&nbsp; The study compares the frequency of SSRI use in subjects with and without a diagnosis of pulmonary tuberculosis and determines that SSRI use is not associated with pulmonary tuberculosis.&nbsp; Which of the following best describes the design of this study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Case-control study"
        },
        {
          "id": 2,
          "text": "Cross-sectional study"
        },
        {
          "id": 3,
          "text": "Prospective cohort study"
        },
        {
          "id": 4,
          "text": "Randomized controlled trial"
        },
        {
          "id": 5,
          "text": "Retrospective cohort study"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"6804\" src=\"https://www.uworld.com/media/L13767.jpg\" ></p><p><strong>Research studies</strong> are broadly classified as having an observational or experimental design depending on the control the researcher has over the independent variables (eg, exposure to risk factors, treatments).</p><ul><li><p>In <strong>observational studies</strong> (eg, case series, case-control studies, cohort studies, cross-sectional studies), the researcher has <strong>no control</strong> over the independent variables (eg, exposures, risk factors).</p></li><li><p>In <strong>experimental studies</strong> (eg, randomized controlled trials), the researcher <strong>controls</strong> and randomly assigns the independent variables (eg, treatments, interventions).</p></li></ul><p>A <strong>case-control</strong> study is an observational design in which potential participants are initially identified as <strong>cases</strong> or <strong>controls</strong> according to the <strong>dependent variable or outcome</strong> (eg, disease of interest).&nbsp; In the study described above, subjects age 20-84&thinsp; newly diagnosed with pulmonary tuberculosis are cases, and subjects without pulmonary tuberculosis are controls.&nbsp; Once cases and controls are identified, the presence of past exposure to &#8805;1 <strong>risk factors</strong> of interest is determined in each group.&nbsp; In this study, the risk factor is selective serotonin reuptake inhibitor (SSRI) use (&#x22;never users&#x22; are subjects who never had a prescription for an SSRI, and &#x22;users&#x22; are subjects who have had a prescription for an SSRI).&nbsp; Finally, the <strong>frequency</strong> of exposure to the risk factor&nbsp;is compared between cases and controls to estimate the <strong>association</strong> between the risk factor&nbsp;and the outcomes.&nbsp; Conducted as designed, this study can determine if SSRI use is associated with pulmonary tuberculosis.</p><p><strong>(Choice B)</strong>&nbsp; In contrast to participants in a case-control study, who are selected based on outcome status (eg, presence or absence of tuberculosis), participants in a cross-sectional study are randomly selected from a population of interest (eg, random sample from a region with high tuberculosis prevalence) and then simultaneously categorized according to risk factor (eg, SSRI use) and outcome (eg, tuberculosis) status.&nbsp; The goal is to determine prevalence by providing a snapshot of the population.</p><p><strong>(Choices C and E)</strong>&nbsp; In a cohort study, 2 groups of individuals (ie, cohorts) are initially identified based on their exposure status to a specific risk factor (eg, SSRI use) rather than based on their outcome status (eg, pulmonary tuberculosis), as seen in this example.&nbsp; These 2 cohorts are then followed over time (ie, prospectively) to assess development of the outcome.&nbsp; Sometimes the exposure status is determined retrospectively, typically using medical records, and patients are tracked from the point of exposure onward.</p><p><strong>(Choice D)</strong>&nbsp; A randomized controlled trial follows individuals who have been randomized to either a treatment arm or a control arm and compares the effect of the intervention.</p><p><strong>Educational objective:</strong><br>A case-control study is an observational study design; it begins with individuals who have the outcome (cases) and compares them with individuals who do not have the outcome (controls) according to history of exposure to &#8805;1 risk factors.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "13474",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A hospital wants to estimate the prevalence of diabetic nephropathy in the surrounding population of adults with type 2 diabetes.&nbsp; Kidney biopsy samples are obtained from 500 adult patients with diabetes who receive care at the hospital.&nbsp; The samples are then interpreted by 10 different pathologists, 5 of whom work at the hospital and 5 of whom work at nearby institutions.&nbsp; A preliminary analysis shows that the pathologists who work for the hospital are 3 times more likely to interpret the biopsy samples as diabetic nephropathy compared to those who do not work for the hospital.&nbsp; Which of the following most likely explains this difference in interpretation?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Confounding"
        },
        {
          "id": 2,
          "text": "Lead-time bias"
        },
        {
          "id": 3,
          "text": "Observer bias"
        },
        {
          "id": 4,
          "text": "Recall bias"
        },
        {
          "id": 5,
          "text": "Selection bias"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Bias</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Observer bias</strong> (also known as expectancy bias) occurs when investigators <strong>misclassify data</strong> due to preconceived expectations or <strong>prior knowledge</strong> concerning the study or its participants.&nbsp; This type of bias is particularly important when outcomes are <strong>subjective</strong> (ie, involve personal interpretation of clinical, microscopic, or radiographic findings).</p><p>In this case, the pathologists who work at the hospital where the study is being conducted may know that the study is investigating diabetic nephropathy, or they may have access to additional medical records that indicate diabetes status.&nbsp; Conversely, the pathologists at other institutions are more likely to be blinded to the study&#39;s objectives and the patients&#39; medical history.</p><p><strong>(Choice A)</strong>&nbsp; A confounder is an extraneous variable that is related to the exposure under investigation but that is also an independent risk factor for a disease.&nbsp; Confounding distorts the relationship between the exposure and the disease.&nbsp; For example, fatty food intake is a potential confounder in a study evaluating the association between physical activity and obesity, as people who do not exercise regularly may be more likely to consume a high-fat diet.</p><p><strong>(Choice B)</strong>&nbsp; <a href=\"1392\">Lead-time bias</a> refers to the apparent prolongation of survival in patients who undergo a screening test that allows for earlier diagnosis but does not actually improve prognosis.&nbsp; For example, a patient with pancreatic cancer presents with metastases at age 58 for which he receives treatment, but he dies at age 60.&nbsp; Had the same patient been screened and diagnosed with pancreatic cancer at age 55, he would have received earlier treatment, but the disease could have progressed such that he would have still died at age 60 (ie, age at death would not have been affected by screening).</p><p><strong>(Choice D)</strong>&nbsp; Recall bias results from inaccurate recall of past exposure by people in a study; it applies most often to retrospective designs such as case-control studies.&nbsp; People who have experienced an adverse outcome are more likely to recall previous risk factors than people who have not experienced an adverse outcome.</p><p><strong>(Choice E)</strong>&nbsp; Selection bias can occur with inappropriate (ie, nonrandom) selection methods or through selective attrition of the study participants.&nbsp; For example, many patients drop from a clinical trial due to the severity of side effects associated with the treatment.&nbsp; This type of attrition is selective (ie, different attrition rates between groups) and reduces the generalizability of the study.</p><p><strong>Educational objective:</strong><br>Observer bias occurs when the investigator&#39;s evaluation is affected by preconceived expectations or prior knowledge, typically leading to overestimation of the disease association or treatment effects.&nbsp; This type of bias can be reduced by conducting a blinded study in which observers are unaware of study details and patient characteristics that could unduly influence them.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1275",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study evaluated the role of angiotensin-converting enzyme (ACE) inhibitors in the prevention of coronary events in patients with diabetes.&nbsp; During 5 years of follow-up, 120 out of 400 diabetic patients who had taken an ACE inhibitor developed an acute coronary event.&nbsp; Over the same time, 100 out of 300 diabetic patients who had not taken an ACE inhibitor experienced coronary events.&nbsp; What was the relative risk of developing a coronary event in diabetic patients who were taking ACE inhibitors compared to diabetic patients who were not taking ACE inhibitors?</p>",
      "choices": [
        {
          "id": 1,
          "text": "(120x100)/(280x200)"
        },
        {
          "id": 2,
          "text": "(120x200)/(100x280)"
        },
        {
          "id": 3,
          "text": "(120x280)/(100x200)"
        },
        {
          "id": 4,
          "text": "(120/220)/(280/480)"
        },
        {
          "id": 5,
          "text": "(120/400)/(100/300)"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Risk</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>It is important to know how to calculate some basic measures of association when given raw data.&nbsp; The first step is to organize the data into a 2&times;2 (contingency) table as shown below.&nbsp; The <a href=\"1811\">standard format</a> includes the exposures in the rows (with &#x22;exposure present&#x22; listed above &#x22;exposure absent&#x22;) and the outcomes in the columns (with &#x22;outcome present&#x22; listed before &#x22;outcome absent&#x22;).</p><blockquote><table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"><tbody align=\"center\"><tr><td></td><td>Coronary event</td><td>No coronary event</td><td></td></tr><tr><td align=\"left\">ACE inhibitor</td><td>120 (a)</td><td>280 (b)</td><td>400</td></tr><tr><td align=\"left\">No ACE inhibitor</td><td>100 (c)</td><td>200 (d)</td><td>300</td></tr><tr><td></td><td>220</td><td>480</td><td>700</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></blockquote><p>The relative risk (RR) represents the risk of an outcome (eg, coronary event) in the exposed (eg, angiotensin-converting enzyme [ACE] inhibitor) divided by the risk of that outcome in the unexposed (eg, no ACE inhibitor).&nbsp; For cohort studies, it is calculated using the following formula:</p><p>RR = [a/(a+b)] / [c/(c+d)] = (120/400)/(100/300) = 0.90</p><p>Understanding the values calculated (rather than memorizing several formulas) would prevent errors that could occur if the standard format for the 2&times;2 table is not followed.&nbsp; By definition, RR = risk among the exposed/risk among the unexposed.&nbsp; In this example, 400 diabetic patients were taking ACE inhibitors (exposed) and 120 of those had a coronary event.&nbsp; Therefore, the risk among the exposed is 120/400.&nbsp; Similarly, 300 diabetic patients were not taking ACE inhibitors (unexposed) and 100 of those had a coronary event.&nbsp; Therefore, the risk among the unexposed is 100/300.&nbsp; The RR is the ratio of those 2 values: RR = (120/400)/(100/300).</p><p><strong>(Choice B)</strong>&nbsp; The odds ratio (OR) is calculated using the following formula: OR = ad/bc.&nbsp; The OR is often calculated in case-control studies where RR cannot be obtained because such studies do not follow patients over time to determine the incidence of a new outcome.</p><p><strong>Educational objective:</strong><br>The relative risk (RR) represents the risk of an outcome in the exposed divided by the risk of that outcome in the unexposed.&nbsp; Applying the correct formula for RR calculations depends on the proper formatting of a 2&times;2 (contingency) table.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1207",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 45-year-old man comes to the office for a routine visit.&nbsp; The patient has a first-degree relative with Alzheimer dementia and is concerned about his chances of developing the disease.&nbsp; He has read in the newspaper that decreased consumption of yellow and orange fruits and vegetables has been associated with Alzheimer disease and would like to know how likely he is to develop the disease.&nbsp; A medical literature review uncovers a recent cohort study that evaluated the association between blood carotene concentration and Alzheimer disease.&nbsp; The development of the disease was evaluated in a 20-year follow-up study of 200 middle-aged subjects who have a first-degree relative with Alzheimer disease.&nbsp; The results are as follows:</p><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr align=\"center\"><td></td><td><strong>Low<br>carotene level</strong></td><td><strong>Normal<br>carotene level</strong></td><td><strong>Total</strong></td></tr><tr align=\"center\"><td><strong>Developed Alzheimer disease</strong></td><td>18</td><td>42</td><td>60</td></tr><tr align=\"center\"><td><strong>Did not develop Alzheimer disease</strong></td><td>27</td><td>113</td><td>140</td></tr><tr align=\"center\"><td><strong>Total</strong></td><td>45</td><td>155</td><td>200</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Assuming the patient has low carotene levels, what is his 20-year risk of developing Alzheimer disease?</p>",
      "choices": [
        {
          "id": 1,
          "text": "0.19"
        },
        {
          "id": 2,
          "text": "0.23"
        },
        {
          "id": 3,
          "text": "0.27"
        },
        {
          "id": 4,
          "text": "0.30"
        },
        {
          "id": 5,
          "text": "0.40"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Risk</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Risk</strong> is the probability of developing a disease or other health outcome over the study period.&nbsp; In this example, it represents the probability of developing Alzheimer disease over a 20-year period among middle-aged subjects who have a first-degree relative with the disease.&nbsp; To calculate this probability in subjects with low carotene levels, divide the number of subjects who develop Alzheimer disease in the low carotene group (18) by the overall number of subjects in the low carotene group (18 + 27 = 45).</p><blockquote>Risk of developing Alzheimer disease among subjects with low carotene = 18 / (18 + 27)<br>= 18 / 45 = <strong>0.40</strong></blockquote><p>This means that, among subjects with low carotene levels, there is a 40% probability of developing Alzheimer disease in 20 years.</p><p>Note that this is different from the <strong>relative risk (RR)</strong> of Alzheimer disease in subjects with low carotene levels compared to those with normal carotene groups:</p><blockquote>RR = risk of developing Alzheimer disease among subjects with low carotene levels / risk of developing Alzheimer disease among subjects with normal carotene levels = 0.4 / [42 / (42 + 113)]&nbsp; = 0.4 / 0.27 = 1.48</blockquote><p>As the data is not presented in the standard <a href=\"1811\">2 &times; 2 (contingency) table format</a>, care must be taken to perform the calculations without relying on memorized formulas.</p><p><strong>(Choices A and D)</strong>&nbsp; The prevalence of low carotene (exposure) among subjects who do not develop Alzheimer disease is 27 / (27 + 113) = 27 / 140 = 0.19 (19%).&nbsp; The prevalence of low carotene (exposure) among subjects who develop Alzheimer disease is 18 / (18 + 42) = 18 / 60 = 0.3 (30%).</p><p><strong>(Choice B)</strong>&nbsp; The prevalence of low carotene in the entire cohort is (18 + 27) / (18 + 42 + 27 + 113) = 45 / 200 = 0.23 (23%).</p><p><strong>(Choice C)</strong>&nbsp; As noted in the RR calculation above, the 20-year risk of developing Alzheimer disease among subjects with normal carotene levels is 42 / (42 + 113) = 42 / 155 = 0.27 (27%).</p><p><strong>Educational objective:</strong><br>Risk is the probability of developing a disease over a certain period of time.&nbsp; To calculate this probability, divide the number of affected subjects by the total number of subjects in the corresponding exposure group.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1185",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Researchers want to estimate the association between environmental lead exposure and cognitive deficits in children.&nbsp; Among all children who received preventive care at 5 local pediatric clinics over the last 5 years, they identify 20 children diagnosed with cognitive deficits and 40 without the diagnosis.&nbsp; The researchers then review the patients&#39; medical records and calculate the distance between the patients&#39; residence and known lead-contaminated geographic areas.&nbsp; Which of the following best describes the study design used by the researchers?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Case-control study"
        },
        {
          "id": 2,
          "text": "Case series study"
        },
        {
          "id": 3,
          "text": "Cross-sectional study"
        },
        {
          "id": 4,
          "text": "Prospective cohort study"
        },
        {
          "id": 5,
          "text": "Randomized control trial"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"6804\" src=\"https://www.uworld.com/media/L13767.jpg\" ></p><p><strong>Observational studies</strong> (eg, case series, case-control studies, cohort studies, cross-sectional studies) differ from experimental studies (eg, clinical trials) in that the researchers passively observe the study participants rather than monitor the result of a specific intervention.&nbsp; Observational studies can be subdivided as follows:</p><ul><li><p>Descriptive studies collect data to characterize a specific health problem (eg, disease prevalence, incidence rates).</p></li><li><p>Analytical studies test hypotheses to evaluate associations between risk factors and disease.</p></li></ul><p>A <strong>case-control</strong> study is an analytical observational design in which potential participants are initially identified as &#x22;<strong>cases</strong>&#x22; or &#x22;<strong>controls</strong>&#x22; according to an <strong>outcome status</strong> (ie, disease of interest).&nbsp; In this example, children diagnosed with cognitive deficits are cases and children without cognitive deficits are controls.&nbsp; Once identified, cases and controls are then <strong>assessed retrospectively</strong> for exposure to <strong>risk factors</strong> of interest.&nbsp; In this case, the risk factor of interest is environmental lead exposure, as measured by the distance between the patients&#39; residence and known lead-contaminated areas.&nbsp; Finally, the prevalence of exposure to the risk factors (ie, frequency of exposure) is compared between cases and controls to estimate the <strong>association</strong> between the risk factors and the outcomes.</p><p><strong>(Choice B)</strong>&nbsp; A case series study is a descriptive study that tracks patients with a known condition (eg, exposure, risk factor, disease) to document the natural history or response to treatment.&nbsp; Unlike a case-control study, a case series is purely descriptive and cannot establish associations.</p><p><strong>(Choice C)</strong>&nbsp; Cross-sectional studies may evaluate associations between risk factors and outcomes of interest.&nbsp; However, unlike in case-control studies (participants selected based on the outcome status), the participants in a cross-sectional study are selected based on the inclusion and exclusion criteria set for the study.</p><p><strong>(Choice D)</strong>&nbsp; In cohort studies, 2 groups of individuals (ie, cohorts) are initially identified based on their exposure status to a specific risk factor (eg, environmental lead exposure) rather than based on their outcome status (eg, cognitive deficits), as seen in this example.&nbsp; The cohorts are then followed over time for development of the outcome.</p><p><strong>(Choice E)</strong>&nbsp; A randomized clinical trial would follow individuals who have been randomized to either a treatment arm or a control arm and compare the effect of the intervention.</p><p><strong>Educational objective:</strong><br>A case-control study is an observational study design; it begins with selecting individuals who have the outcome (&#x22;cases&#x22;) and individuals who do not have the outcome (&#x22;controls&#x22;) and then retrospectively comparing their history of exposure to risk factors.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "13479",
      "difficulty": "N/A"
    },
    {
      "text": "<p>The aim of a prospective cohort study conducted in a group of adults with diagnosed type 2 diabetes mellitus (T2DM) is to investigate the association between the presence of morbid obesity (BMI &gt;40 kg/m<font size=\"2\"><sup>2</sup></font>) and the risk of developing diabetic nephropathy.&nbsp; One of the groups in the study consists of adults with T2DM, a BMI &gt;40 kg/m<font size=\"2\"><sup>2</sup></font>, and no diabetic nephropathy.&nbsp; Which of the following is the most appropriate comparison group for this prospective cohort study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Adults with T2DM who have morbid obesity (BMI &gt;40 kg/m2) and diabetic nephropathy"
        },
        {
          "id": 2,
          "text": "Adults with T2DM who have normal weight (BMI 18.5 to &lt;25 kg/m2) and diabetic nephropathy"
        },
        {
          "id": 3,
          "text": "Adults with T2DM who have normal weight (BMI 18.5 to &lt;25 kg/m2) and no diabetic nephropathy"
        },
        {
          "id": 4,
          "text": "Adults without T2DM who have morbid obesity (BMI &gt;40 kg/m2) and no diabetic nephropathy"
        },
        {
          "id": 5,
          "text": "Adults without T2DM who have normal weight (BMI 18.5 to &lt;25 kg/m2) and diabetic nephropathy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"38297\" src=\"https://www.uworld.com/media/L63828.png\" ></p><p>A <strong>cohort study</strong> is an observational design in which potential participants in the <strong>population of interest</strong> are initially <strong>identified as exposed or nonexposed</strong> according to the independent variable (ie, exposure status to a risk factor).&nbsp; Once participants are categorized based on their exposure status, the occurrence (ie, incidence) of the dependent variable (eg, <strong>outcome of interest</strong>) over a specific period is determined in each group.&nbsp; Finally, the occurrence of the outcome is compared between exposed and nonexposed groups to estimate the association between the risk factors and the outcomes.&nbsp; If there is a statistically significant difference in outcome occurrence between the 2 groups, it is likely that the risk factor in question is associated with disease development.</p><p>In this example:</p><ul><li><p>The <strong>population</strong> of interest is patients with <strong>type 2 diabetes mellitus</strong> (T2DM).&nbsp; Therefore, both the exposed and nonexposed groups must consist of patients with T2DM <strong>(Choices D and E)</strong>.</p></li><li><p>The <strong>risk factor</strong> of interest is <strong>morbid obesity</strong> (BMI &gt;40 kg/m<font size=\"2\"><sup>2</sup></font>).&nbsp; Therefore, the exposed group is adults with morbid obesity, and the nonexposed group is adults with normal weight (BMI 18.5 to &lt;25 kg/m<font size=\"2\"><sup>2</sup></font>) <strong>(Choice A)</strong>.</p></li><li><p>The <strong>outcome</strong> of interest is <strong>diabetic nephropathy</strong>.&nbsp; Exposed and nonexposed subjects must be selected with <strong>no history</strong> of the outcome because the occurrence of the outcome is what is measured during the study period <strong>(Choice B)</strong>.</p></li></ul><p>Therefore, the exposed group is adults with T2DM who have morbid obesity and no diabetic nephropathy; the <strong>nonexposed group</strong> is adults <strong>with T2DM</strong> who have <strong>normal weight</strong> (BMI 18.5 to &lt;25 kg/m<font size=\"2\"><sup>2</sup></font>) and <strong>no diabetic nephropathy</strong>.&nbsp; Comparing the frequency of the outcome (eg, diabetic nephropathy) between exposed and nonexposed groups is what determines whether exposure to the risk factor (eg, morbid obesity) is associated with the risk of developing the outcome (eg, diabetic nephropathy).</p><p><strong>Educational objective:</strong><br>In a cohort study, subjects should be initially selected from the population of interest (eg, T2DM) based on their exposure status to a risk factor (eg, presence or absence of morbid obesity).&nbsp; Subjects are then monitored during the study period for development of the outcome of interest (eg, diabetic nephropathy).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "13476",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Officials of a public health department report a higher than normal prevalence of acute myelogenous leukemia (AML) among children age 5-12 in their community.&nbsp; They observe that some households in the community are exposed to chemical waste from a nearby factory and worry that exposure to this waste is responsible for the increased prevalence of AML.&nbsp; A case-control study is designed to evaluate the health department officials&#39; claim that exposure to chemical waste is associated with AML in childhood.&nbsp; Which of the following populations should be selected as the control group?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Children who do not have AML and are exposed to chemical waste"
        },
        {
          "id": 2,
          "text": "Children who do not have AML and are not exposed to chemical waste"
        },
        {
          "id": 3,
          "text": "Children who do not have AML, regardless of exposure status to chemical waste"
        },
        {
          "id": 4,
          "text": "Children who have AML and are exposed to chemical waste"
        },
        {
          "id": 5,
          "text": "Children who have AML and are not exposed to chemical waste"
        },
        {
          "id": 6,
          "text": "Children who have AML, regardless of exposure status to chemical waste"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"10560\" src=\"https://www.uworld.com/media/L34769.jpg\" ></p><p>A <strong>case-control study</strong> is the most appropriate study design for evaluating the public health officials&#39; claim.&nbsp; This is because the disease (acute myelogenous leukemia [AML]) is a rare condition occurring at a higher rate in this population, and a retrospective exposure (chemical waste exposure) needs to be evaluated.&nbsp; In case-control studies, 2 groups of subjects are created: <strong>cases</strong> (subjects <strong>with</strong> the disease of interest) and <strong>controls</strong> (subjects <strong>without</strong> the disease of interest).&nbsp; After the case and control groups are selected, exposure frequency to a specific variable (eg, chemical waste) within both groups is ascertained.&nbsp; If there is a statistically significant difference in exposure frequency between the 2 groups, it is likely that the variable in question is associated with disease development.</p><p>In this example, AML is the disease of interest; therefore, children with AML should be used as cases and children <strong>without AML</strong> should be used as <strong>controls</strong>.&nbsp; Cases and controls should be selected <strong>regardless</strong> of exposure status to the chemical waste <strong>(Choices A and B)</strong>.&nbsp; Selecting subjects based on exposure status is inappropriate because comparing the frequency of exposure between the case and control groups is what determines whether the exposure is more prevalent among cases as compared to controls.</p><p>Ideally, exposure frequency among controls should be representative of that among the population of individuals &#x22;at risk&#x22; of becoming cases.&nbsp; In other words, for a given case-control study, controls are nondiseased individuals who could be considered cases if they had the disease.&nbsp; Often, controls and cases are matched based on independent variables (eg, age, sex) to decrease the effects of confounding.</p><p><strong>(Choices D, E, and F)</strong>&nbsp; AML is the outcome of interest; therefore, children who have AML can be used only to form the cases group and cannot be used as controls.&nbsp; Cases should also be selected regardless of exposure status.</p><p><strong>Educational objective:</strong><br>Selection of control subjects in case-control studies is intended to provide an accurate estimation of exposure frequency among the nondiseased general population.&nbsp; Cases and controls should be selected based on disease status, not exposure status.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1202",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study to assess spironolactone&#39;s efficacy in patients with heart failure is performed.&nbsp; 450 patients receive either spironolactone or placebo for two years.&nbsp; Neither the patients nor physicians are aware of who takes the drug or placebo.&nbsp; The study setup described above is most effective in preventing:</p>",
      "choices": [
        {
          "id": 1,
          "text": "Beta error"
        },
        {
          "id": 2,
          "text": "Recall bias"
        },
        {
          "id": 3,
          "text": "Observer bias"
        },
        {
          "id": 4,
          "text": "Effect modification"
        },
        {
          "id": 5,
          "text": "Selection bias"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Bias</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>Blinding technique is commonly used in clinical trials.&nbsp; The blinding can involve patients exclusively or both patients and physicians (double blinding).&nbsp; The main purpose of blinding is to prevent patient or researcher expectancy from interfering with the determination of an outcome.&nbsp; For example, a researcher&#39;s belief in a positive outcome in treated patients can potentially result in observer bias.</p><p><b>(Choice A)</b>&nbsp; Beta error refers to a conclusion that there is no difference between the groups studied when a difference truly exists.&nbsp; Beta error is a random error, not a systematic error (i.e., bias).</p><p><b>(Choice B)</b>&nbsp; Recall bias results from the inaccurate recall of past exposure by subjects.&nbsp; It applies mostly to case-control studies.</p><p><b>(Choice D)</b>&nbsp; Effect modification is not a bias and should not be controlled.</p><p><b>(Choice E)</b>&nbsp; Selection bias results from the manner in which people are selected for the study, or from the selective losses from follow-up.</p><p><b>Educational Objective:</b><br>The main purpose of blinding is to prevent patient or researcher expectancy from interfering with an outcome.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1301",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A group of sports physicians plans to conduct a case-control study to investigate a possible association between adolescent idiopathic scoliosis (AIS) and sacroiliac joint (SIJ) dysfunction in young athletes.&nbsp; The case group will consist of young athletes who were diagnosed with AIS during a regular checkup by a sports physician.&nbsp; Which of the following is the most appropriate control group for this study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Young athletes with a diagnosis of AIS and SIJ"
        },
        {
          "id": 2,
          "text": "Young athletes with a diagnosis of AIS but not of SIJ"
        },
        {
          "id": 3,
          "text": "Young athletes with a diagnosis of AIS irrespective of SIJ status"
        },
        {
          "id": 4,
          "text": "Young athletes with no diagnosis of AIS irrespective of SIJ status"
        },
        {
          "id": 5,
          "text": "Young athletes with no diagnosis of AIS or SIJ"
        },
        {
          "id": 6,
          "text": "Young nonathletes with a diagnosis of AIS but not of SIJ"
        },
        {
          "id": 7,
          "text": "Young nonathletes with a diagnosis of AIS irrespective of SIJ status"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"6804\" src=\"https://www.uworld.com/media/L13767.jpg\" ></p><p>A <strong>case-control</strong> study is an observational design in which potential participants are initially identified as <strong>cases</strong> or <strong>controls</strong> according to the <strong>dependent variable or outcome</strong> (eg, disease of interest).&nbsp; Once cases and controls are identified, the presence of past exposure to &#8805;1 <strong>risk factors</strong> of interest is determined in each group.&nbsp; Finally, the <strong>frequency</strong> of exposure to the risk factors is compared between cases and controls to estimate the <strong>association</strong> between the risk factors and the outcomes.&nbsp; If there is a statistically significant difference in the frequency of exposure to the risk factor between the 2 groups, it is likely that the risk factor in question is associated with the disease.</p><p>In this example:</p><ul><li><p>The population of interest is young athletes.&nbsp; Therefore, both the cases and control groups must consist of young athletes <strong>(Choices F and G)</strong>.</p></li><li><p>The disease of interest (ie, what defines a case) is adolescent idiopathic scoliosis (AIS).&nbsp; Therefore, the cases must have AIS and controls must not have AIS<strong> (Choices A, B, and C)</strong>.</p></li><li><p>The risk factor of interest is sacroiliac joint (SIJ) dysfunction.&nbsp; Cases and controls must be selected irrespective of SIJ status because the presence of SIJ is what is compared between cases and controls <strong>(Choice E)</strong>.</p></li></ul><p>Therefore, the cases are young athletes with a diagnosis of AIS irrespective of SIJ status; the <strong>controls</strong> are <strong>young athletes</strong> with <strong>no diagnosis of AIS irrespective of SIJ status</strong> because what determines whether the disease (ie, AIS) is associated with the risk factor (ie, SIJ) is the difference in the frequency of the risk factor between cases and controls.</p><p><strong>Educational objective:</strong><br>A case-control study is an observational study design; it begins with individuals who have the outcome (&#x22;cases&#x22;) and compares them with individuals who do not have the outcome (&#x22;controls&#x22;) according to history of exposure to &#8805;1 risk factors.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "18274",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A surveillance study is conducted to assess the long-term efficacy and safety of a drug currently being used to treat patients with heart failure.&nbsp; Researchers enroll 8,300 patients with heart failure.&nbsp; The patients receive the drug once daily for 6 months.&nbsp; The results show significant clinical improvement, but severe hypernatremia is observed in 23 patients.&nbsp; The study publication recommends a lower dose of the drug in patients with baseline normonatremia and hypokalemia to prevent hypernatremia.&nbsp; Which of the following best characterizes this type of study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Phase I clinical trial"
        },
        {
          "id": 2,
          "text": "Phase II clinical trial"
        },
        {
          "id": 3,
          "text": "Phase III clinical trial"
        },
        {
          "id": 4,
          "text": "Phase IV clinical trial"
        },
        {
          "id": 5,
          "text": "Preclinical study"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Clinical trials</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img  draggable=\"false\" id=\"55399\" src=\"https://www.uworld.com/media/highresdefault/L67113.jpg\"  ></p><p>Efficacy and safety of new drugs are established during the <strong>clinical trials process</strong>.&nbsp; New drugs are approved by a regulatory body (ie, Food and Drug Administration) following review of <strong>phase I-III</strong> trials.&nbsp; Phases differ in size, objective, and participant selection.</p><ul><li><p><strong>Phase I:</strong>&nbsp; Assesses safety and pharmacokinetics.&nbsp; Phase I is usually conducted with a small number (eg, 20-80) of healthy participants.&nbsp; It often is performed in a strictly controlled environment with extensive biochemical and physiologic monitoring.</p></li><li><p><strong>Phase II:</strong>&nbsp; Assesses preliminary efficacy and optimal dosing.&nbsp; Phase II is conducted with a small number of participants who have the condition of interest, and patient outcomes are often compared to historical controls.&nbsp; It sometimes is called a pilot study.</p></li><li><p><strong>Phase III:</strong>&nbsp; Compares treatment to standard of care.&nbsp; Phase III is conducted as a large, randomized, controlled trial (in contrast to this study, which is a surveillance study with no control group) to better assess treatment response and safety.&nbsp; It may include analysis of treatment effects in selected subsets of the target patient population.</p></li></ul><p>The description of this study of a currently available drug is most consistent with a <strong>phase IV (postmarketing) study</strong>, which is conducted <strong>after regulatory approval</strong> of the drug.&nbsp; Phase IV assesses <strong>long-term safety and effectiveness</strong> and characterizes uncommon or <strong>delayed adverse effects</strong>.&nbsp; It typically involves surveillance of a large number of treated participants to detect small effects and variability in diverse patient populations.&nbsp; The results are often used to refine the use of the drug in clinical practice.</p><p><strong>(Choice E)</strong>&nbsp; Preclinical studies are typically conducted without human subjects (ie, bench research) largely to determine the mechanism of action and/or make a preliminary estimation of safety and efficacy.</p><p><strong>Educational objective:</strong><br>Phase IV (postmarketing) trials are conducted with drugs that have already been approved for use in order to study long-term effectiveness and better characterize uncommon or delayed adverse effects.&nbsp; They are typically designed to identify small treatment effects (ie, a high power study with large numbers of participants) in diverse patient populations, and the results may be used to refine the use of drugs in clinical practice.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17938",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A geneticist is interested in the potential causes of a congenital abnormality.&nbsp; She hypothesizes that acetaminophen use during the first trimester of pregnancy might be associated with the abnormality.&nbsp; In her study, a sample of mothers of children with and without the abnormality are randomly selected from government birth records.&nbsp; Personal interviews are then conducted with the mothers to determine fetal exposure to acetaminophen.&nbsp; Results show that mothers of children who do not have the abnormality did not take acetaminophen as frequently during the first trimester.&nbsp; This type of study is most susceptible to which of the following types of bias?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Allocation bias"
        },
        {
          "id": 2,
          "text": "Detection bias"
        },
        {
          "id": 3,
          "text": "Recall bias"
        },
        {
          "id": 4,
          "text": "Referral bias"
        },
        {
          "id": 5,
          "text": "Selection bias"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Bias</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Recall bias</strong> results from study participants&#39; <strong>inaccurate recall</strong> of past exposure and occurs most often in <strong>retrospective</strong> studies such as <strong>case-control</strong> studies.&nbsp; People who have experienced an adverse event (eg, congenital abnormalities in their children) are more likely to recall previous potential risk factors (eg, acetaminophen use) than people who have not experienced an adverse event.</p><p>Contrary to case-control studies, which evaluate exposure to potential risk factors retrospectively, <strong>prospective studies</strong> begin with exposed and unexposed individuals.&nbsp; Because the exposure status is determined at the time of enrollment in the study, recall bias is <strong>minimized</strong>.</p><p><strong>(Choice A)</strong>&nbsp; Allocation bias can result from the way patients are <em>assigned</em> to the treatment and control groups.&nbsp; It may occur when subjects are nonrandomly assigned to the study groups of a clinical trial (eg, physicians may preferentially enroll sicker patients into the experimental group).&nbsp; Allocation bias is different from selection bias, which occurs when the studied sample does not represent the general population (eg, because of <em>nonrandom selection</em>).</p><p><strong>(Choice B)</strong>&nbsp; Detection bias refers to the fact that a risk factor itself may lead to extensive diagnostic investigation and increase the probability that a disease is identified.&nbsp; For instance, patients who smoke may undergo increased imaging surveillance due to their smoking status, which would detect more cases of cancer in general.</p><p><strong>(Choice D)</strong>&nbsp; Referral (admission rate) bias occurs when the case and control populations differ due to admission or referral practices.&nbsp; For instance, a study involving asbestos as a risk factor for lung cancer conducted at a hospital specializing in treating asbestosis may select patients with lung cancer (cases) from the respiratory department and a control group without lung cancer from other departments.&nbsp; Because the hospital specializes in asbestosis treatment, patients in the respiratory department with lung cancer are more likely to have a history of asbestos exposure (compared to patients with lung cancer at other, nonspecialized institutions).&nbsp; Therefore, the study may erroneously report a stronger association than actually exists.</p><p><strong>(Choice E)</strong>&nbsp; Selection bias occurs when the method of selection used in a particular study results in selection sample of participants who are not representative of the intended population.&nbsp; A common example is patients with cancer who fail standard therapy and who are therefore the most likely to enroll in experimental trials (self-selection), leading to results that are not applicable to patients with less advanced cancers.</p><p><strong>Educational objective:</strong><br>Recall bias results from study participants&#39; inaccurate recall of past exposure and occurs most often in retrospective studies such as case-control studies.&nbsp; People who have experienced an adverse event are more likely to recall risk factors than those who have not experienced an adverse event.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1273",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Inflammatory biological markers are clinically useful in a number of different ways, one being the assessment of disease activity in conditions such as systemic lupus erythematosus (SLE).&nbsp; A new inflammatory marker is being investigated in patients with active SLE flares.&nbsp; When the blood level of the new marker (in mg/L) is plotted against the C-reactive protein (CRP) level (also in mg/L), the following plot is obtained:</p><p><img id=\"9122\"  src=\"https://www.uworld.com/media/BioStatsCorrelationCoeff.gif\" draggable=\"false\" ></p><p>Based on the plot, the correlation coefficient between the 2 variables is closest to which of the following values?</p>",
      "choices": [
        {
          "id": 1,
          "text": "+0.8"
        },
        {
          "id": 2,
          "text": "+0.2"
        },
        {
          "id": 3,
          "text": "0"
        },
        {
          "id": 4,
          "text": "&#8722;0.2"
        },
        {
          "id": 5,
          "text": "&#8722;0.8"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Correlation coefficient</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"6794\"  src=\"https://www.uworld.com/media/L24110.jpg\" draggable=\"false\" ></p><p>Scatter plots are useful for crude data analysis.&nbsp; If a <strong>linear</strong> association is present between 2 variables, a <strong>correlation coefficient</strong> (r) mathematically describes how well a &#x22;line of best fit&#x22; (blue line in Figure) would correspond to the data points plotted.&nbsp; The value of r ranges from <strong>&#8722;1 to +1</strong> and describes 2 important characteristics of an association: the strength and the polarity.&nbsp; The closer the r value is to its margins [&#8722;1, 1], the stronger the association.</p><p>An increase in C-reactive protein (CRP) level is associated with a decrease in the new marker&#39;s level; therefore, r &lt;0.&nbsp; Although the scatter plot does not demonstrate a perfect linear arrangement, it does show a reasonably strong linear association as there is minimal variation along the line of best fit (points are relatively close to the line).&nbsp; Therefore, the most appropriate answer among the options given is r = &#8722;0.8.</p><p><strong>(Choices A and B)</strong>&nbsp; In this example, r cannot be &gt;0 as an increase in CRP level is associated with a decrease in the new marker&#39;s level.</p><p><strong>(Choice C)</strong>&nbsp; An r = 0 indicates that there is no association (ie, a random distribution).</p><p><strong>(Choice D)</strong>&nbsp; An r = &#8722;0.2 would also indicate a negative association; however, there would be more variation along the line of best fit (as seen in the Figure).</p><p>The value of r is <strong>not</strong> the slope of the line of best fit.&nbsp; For instance, assuming a data set with a maximum positive association (ie, all data points forming a straight line with a positive slope), the line of best fit will always have r = +1, even if its actual slope is 0.2, 5.5, or any other positive value (as seen in the Figure).</p><p><strong>Educational objective:</strong><br>The correlation coefficient (r) ranges from &#8722;1 to +1 and describes the strength and polarity of a linear association.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1210",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Researchers are interested in the association between colorectal carcinoma and nonsteroidal anti-inflammatory drug use.&nbsp; They first interview a group of patients with biopsy-proven colorectal carcinoma and then interview a group consisting of the patients&#39; neighbors who are of similar age and race.&nbsp; The analysis is based on comparing the results of pairs of individuals (one from each of the 2 groups) who have similar characteristics.&nbsp; This design technique best helps address which of the following potential problems with this study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Ascertainment bias"
        },
        {
          "id": 2,
          "text": "Confounding"
        },
        {
          "id": 3,
          "text": "Observer bias"
        },
        {
          "id": 4,
          "text": "Recall bias"
        },
        {
          "id": 5,
          "text": "Selection bias"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Bias</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Matching</strong> is a method generally used in the design stage of case-control studies to control <a href=\"1943\">confounding</a> (ie, when a perceived association between an exposure and an outcome is actually explained by a confounding variable associated with both the exposure and the outcome).&nbsp; The initial step in matching involves selecting variables that could be confounders (eg, age, race).&nbsp; Cases and controls are then selected based on the matching variables so that both groups have a <strong>similar distribution</strong> in accordance with the variables.</p><p>In this scenario, the &#x22;cases&#x22; (patients with colorectal cancer) were matched with neighborhood &#x22;controls&#x22; of similar age and race.&nbsp; Selecting neighbors as controls has another advantage of matching the cases to controls by variables that are difficult to measure (eg, socioeconomic status, environmental factors).&nbsp; Gender and smoking status are other common confounders.</p><p><strong>(Choices A, C, D, and E)</strong>&nbsp; Observer bias and ascertainment bias result from mislabeling exposed/unexposed or cases/controls.&nbsp; Recall bias could be a limitation of this study as the interviewed participants with colorectal cancer may be more likely to recall certain exposures.&nbsp; Selection bias is a potential problem in this study because the controls selected may not reflect the exposure experience of the general population.&nbsp; However, although these biases may be present, matching best addresses confounding rather than any of these biases.</p><p><strong>Educational objective:</strong><br>Matching is used in case-control studies in order to control confounding.&nbsp; Matching variables should always be the potential confounders of the study (eg, age, race).&nbsp; Cases and controls are then selected based on the matching variables so that both groups have a similar distribution in accordance with the variables.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1189",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A new study is conducted to investigate the efficacy of intravenous immunoglobulin versus analgesics on pain alleviation in patients with idiopathic small fiber neuropathy.&nbsp; A total of 100 eligible patients who fulfilled the inclusion/exclusion criteria are assigned to one of two groups based on random selection by a computer.&nbsp; The method of assigning patients to treatment groups in this study is most likely intended to produce which of the following?</p>",
      "choices": [
        {
          "id": 1,
          "text": "One group in which participants are blinded to the intervention they receive and another in which participants are not"
        },
        {
          "id": 2,
          "text": "One group in which researchers but not participants are aware of the intervention received and another in which participants but not researchers are aware of the intervention received"
        },
        {
          "id": 3,
          "text": "Two groups of participants that will only be analyzed based on their initial treatment allocation"
        },
        {
          "id": 4,
          "text": "Two groups that have equal numbers of participants"
        },
        {
          "id": 5,
          "text": "Two groups in which participants are similar in underlying characteristics"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Randomized control trials</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Randomization</strong> refers to the process of <strong>randomly</strong> (ie, by chance) <strong>assigning subjects</strong> to experimental groups (eg, treatment vs control group).&nbsp; Randomization <strong>prevents selection bias</strong> and potentially produces <strong>comparable groups</strong> by balancing the frequency of confounding variables (eg, sex, age, severity of disease) between experimental groups.&nbsp; Making experimental groups as similar as possible (except for the treatment assigned) cancels the effect that these characteristics may have on the outcome of interest.</p><p>For example, having groups that are dissimilar (ie, unbalanced) with respect to severity of disease may underestimate or overestimate the effect of a treatment, depending on which group has a greater proportion of severe cases.&nbsp; The best way to account for the effects of these variables is to randomly assign subjects to experimental groups.&nbsp; Afterward, the groups are analyzed to ensure that they are statistically similar in underlying variables, with the results often reported in a baseline characteristics table (eg,&nbsp;weight, sex, age).</p><p>Therefore, randomization increases the likelihood that any <strong>difference observed between groups is due exclusively to the treatment</strong> and not to other characteristics.</p><p><strong>(Choices A and B)</strong>&nbsp; A blind study is a type of clinical trial in which either the participants or the researchers (ie, single blind) or both the participants and the researchers (ie, double blind) are unaware of treatment assignments.&nbsp; Although this study used randomization to assign patients to treatment groups, no information is provided regarding the awareness of participants or researchers to treatment assignments.&nbsp; By itself, randomization does not make a study blind.</p><p><strong>(Choice C)</strong>&nbsp; A study that analyzes all participants as initially allocated after randomization, regardless of what happens during the study period, is using an intention-to-treat (ITT) analysis.&nbsp; ITT is not a result of randomization; instead, it is used to preserve the effect of randomization.</p><p><strong>(Choice D)</strong>&nbsp; Depending on the randomization method (eg, simple, complete) used to allocate participants into experimental groups, a study may or may not result in groups that are similar in sample size.&nbsp; Regardless, the goal of randomization is not to create groups of similar size (which can be done trivially by alternating group assignment as patients enroll) but rather to make the underlying characteristics of experimental groups as similar as possible.</p><p><strong>Educational objective:</strong><br>Randomization refers to the process of using random methods to assign subjects to experimental groups.&nbsp; Its purpose is to make experimental groups as similar as possible (except for the treatment assignment) to ensure that any difference observed between the groups is due exclusively to the treatment and not to other underlying factors.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17855",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A study compared drug A versus standard therapy in preventing recurrent pulmonary embolism (PE).&nbsp; The absolute risk reduction for drug A versus standard therapy was 4%.&nbsp; The incidence of recurrent PE in the standard therapy group was 6%.&nbsp; There were 24 patients who developed recurrent PE in the drug A group.&nbsp; How many total subjects were there in the drug A group?</p>",
      "choices": [
        {
          "id": 1,
          "text": "600"
        },
        {
          "id": 2,
          "text": "900"
        },
        {
          "id": 3,
          "text": "1200"
        },
        {
          "id": 4,
          "text": "1500"
        },
        {
          "id": 5,
          "text": "1800"
        },
        {
          "id": 6,
          "text": "2100"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Risk</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This question is meant to challenge your knowledge of how absolute risk reductions (ARR) are calculated.&nbsp; The ARR equals the event rate in the control group (ER<font size=\"2\"><sub>control</sub></font>) minus the event rate in the treatment group (ER<font size=\"2\"><sub>treatment</sub></font>).&nbsp; In this example, the event rate represents the incidence of recurrent pulmonary embolism (PE); ER<font size=\"2\"><sub>treatment</sub></font> is the incidence of recurrent PE in the drug A group, and ER<font size=\"2\"><sub>control</sub></font> is the incidence in the standard therapy group.&nbsp; ER<font size=\"2\"><sub>treatment</sub></font> can be determined from the ARR (given as 4%) and ER<font size=\"2\"><sub>control</sub></font> (given as 6%):</p><blockquote>ARR = ER<font size=\"2\"><sub>control</sub></font> &#8722; ER<font size=\"2\"><sub>treatment</sub></font><br>4% = 6% &#8722; ER<font size=\"2\"><sub>treatment</sub></font><br>ER<font size=\"2\"><sub>treatment</sub></font> = 2% = 0.02</blockquote><p>This value (ER<font size=\"2\"><sub>treatment</sub></font>) also represents the number of events in the treatment arm divided by the number of subjects in the treatment arm.&nbsp; Therefore, knowing the total number of events in the treatment arm (24 instances of recurrent PE in the drug A group), the number of subjects in the treatment arm can be easily calculated:</p><blockquote>ER<font size=\"2\"><sub>treatment</sub></font> = Number of events in the treatment arm / Number of subjects in the treatment arm<br>0.02 = 24 / Number of subjects in the treatment arm<br>Number of subjects in the treatment arm = 24 / 0.02 = 1200</blockquote><p><strong>Educational objective:</strong><br>Absolute risk reduction = event rate in the control group &#8722; event rate in the treatment group.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1175",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A prospective study evaluates the relationship between regular antioxidant supplement use (vitamins C and E) and the risk of stroke in healthy and physically active men age 40-60.&nbsp; The study compares the risk of stroke among men who consumed antioxidant supplements for &#8805;5 years and among men who consumed antioxidant supplements for &lt;5 years, as compared to a reference group of men who never consumed antioxidant supplements.&nbsp; According to the study results, men who consumed antioxidant supplements for &lt;5 years and men who consumed antioxidant supplements for &#8805;5 years have stroke relative risks of 0.95 (<em>p</em> = 0.45) and 0.75 (<em>p</em> &lt; 0.01), respectively, when compared to the reference group.&nbsp; The results of the study were adjusted to account for baseline differences related to healthy behaviors and overall health.&nbsp; Which of the following factors most likely explains why the relative risk of stroke is lower with longer antioxidant use?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Accumulation effect"
        },
        {
          "id": 2,
          "text": "Lead-time bias"
        },
        {
          "id": 3,
          "text": "Observer bias"
        },
        {
          "id": 4,
          "text": "Rare disease assumption"
        },
        {
          "id": 5,
          "text": "Selection bias"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Risk</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Antioxidant use</strong> for <strong>&#8805;5 years</strong> was associated with a <strong>statistically significant</strong> (<em>p</em> &lt; 0.01) decreased risk of stroke (relative risk [RR] = 0.75 &lt;1).&nbsp; By contrast, antioxidant use for <strong>&lt;5 years</strong> demonstrated a <strong>nonstatistically significant</strong> (<em>p</em> &gt; 0.05) smaller reduction in risk (RR = 0.95); in other words, antioxidant use for &lt;5 years seems to have no benefit on stroke risk reduction.&nbsp; This discrepancy can be explained if reduction in stroke risk is associated with the <strong>duration of exposure</strong> to antioxidant supplementation; in other words, a minimum cumulative exposure to antioxidants may be necessary for the exposure to have a significant effect on stroke risk.</p><p>This concept of <strong>accumulation effect</strong> can apply to both risk factors and risk reducers.&nbsp; The effect of exposure to risk factors may depend on the duration and intensity of the exposure; long-term exposure may be necessary well before an effect on the disease process is clinically evident (eg, lung cancer developing after decades of smoking exposure).&nbsp; Similarly, exposure to certain <strong>risk reducers</strong> must occur continuously over extended periods before disease outcome is affected.&nbsp; In this case, &#8805;5 years of continuous antioxidant use (risk reducer) were required to reveal their protective effect on stroke.</p><p><strong>(Choice B)</strong>&nbsp; Lead time is the time between the initial detection of a disease and a specific outcome or measured endpoint.&nbsp; <a href=\"1392\">Lead-time bias</a> can occur when a test detects or diagnoses the disease at an earlier stage than another test without impacting the natural history of the disease.&nbsp; A study comparing disease survival times may then erroneously conclude that using the earlier-detection test prolongs survival, when in actuality the increased survival time is due solely to earlier detection of the disease.</p><p><strong>(Choice C)</strong>&nbsp; Observer bias occurs when an observer misclassifies data due to individual differences in interpretation or preconceived expectations regarding a study.&nbsp; It can be reduced by performing a double-blind study (ie, both observers and participants unaware of randomized parameters) and by having multiple observers encode and verify the recorded data.</p><p><strong>(Choice D)</strong>&nbsp; Diseases with a very low incidence rate in the population will also have a very low prevalence.&nbsp; According to the rare disease assumption, the <a href=\"1585\">odds ratio approximates RR</a> when disease prevalence is low (eg, &lt;10%).</p><p><strong>(Choice E)</strong>&nbsp; Selection bias can occur with inappropriate (ie, nonrandom) selection methods or through selective attrition of the study participants.&nbsp; Although selection bias is a possible limitation of the study (eg, individuals who take vitamins daily may be more likely to be already healthy), the fact that the study was limited to healthy, physically active men and that it adjusted for baseline differences should considerably reduce the effect of this potential bias.</p><p><strong>Educational objective:</strong><br>The concept of accumulation effect can be applied to disease pathogenesis and exposure to risk modifiers.&nbsp; Cumulative exposure to a risk factor or risk reducer must sometimes occur for prolonged periods before a clinically significant effect is detected.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1280",
      "difficulty": "N/A"
    },
    {
      "text": "<p>An epidemiologist wants to conduct a study on hepatitis C (HCV) transmission in a country with limited healthcare resources.&nbsp; She has access to a cohort of adults newly diagnosed with HCV and a cohort of age-matched HCV-negative adults.&nbsp; She plans to use these 2 cohorts of adults to conduct a case-control study.&nbsp; Which of the following would be the most appropriate measure of interest for this researcher&#39;s study?</p>",
      "choices": [
        {
          "id": 1,
          "text": "The average death rate in each cohort"
        },
        {
          "id": 2,
          "text": "The frequency of past blood transfusions in each cohort"
        },
        {
          "id": 3,
          "text": "The incidence rate of liver cancer in HCV-positive participants"
        },
        {
          "id": 4,
          "text": "The rate of eventual HCV infection in HCV-negative participants"
        },
        {
          "id": 5,
          "text": "The rate of treatment-related adverse effects in HCV-positive participants"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Case control studies</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"6804\" src=\"https://www.uworld.com/media/L13767.jpg\" ></p><p>A <strong>case-control</strong> study is an observational study design in which potential participants are initially identified as <strong>cases</strong> or <strong>controls</strong> according to their <strong>disease status</strong> (ie, have or do not have the disease of interest).</p><p>In the study described above, a cohort of adults newly diagnosed with hepatitis C (HCV) represents the cases, and a cohort of HCV-negative adults represents the controls.&nbsp; Note that &#x22;cohort&#x22; in this case refers to a group of individuals with similar characteristics (eg, HCV-positivity), not to a &#x22;cohort study,&#x22; in which a group of individuals are followed over time.</p><p>Once cases and controls are identified, the <strong>frequency</strong> of past exposure to &#8805;1 <strong>risk factors</strong> of interest is compared between cases and controls to estimate the <strong>association</strong> between the risk factors and the outcomes.&nbsp; Therefore, an&nbsp;<strong>appropriate&nbsp;</strong><strong>measure</strong> for the proposed study would be any event that <strong>preceded HCV infection</strong>.&nbsp; Among the given choices, a history of <strong>past blood transfusions</strong> precedes HCV infection.</p><p>Because of the retrospective nature of a case-control study, this study design is not able to compare the frequency (ie, incidence, risk, rate) of any event that occurs after a disease has been diagnosed (ie, prospective outcomes).&nbsp; Prospective outcomes are reasonable in cohort studies and experimental designs <strong>(Choices A, C, D, and E)</strong>.</p><p><strong>Educational objective:</strong><br>In a case-control study, potential participants are initially identified as cases or controls according to their disease status.&nbsp; The frequency of past exposure to &#8805;1 risk factors of interest is then compared between cases and controls to estimate the association between the risk factors and the outcomes.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "18224",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A new estrogen receptor agonist is being evaluated for the treatment of postmenopausal symptoms.&nbsp; A prospective study shows that the drug increases the risk of deep vein thrombosis (DVT) in treated women who smoke compared to untreated women who smoke, with a relative risk (RR) of 1.70 and p-value of 0.01.&nbsp; In nonsmokers, no increased risk of DVT is evident with use of the drug (RR = 0.96; p-value = 0.68).&nbsp; Which of the following describes this phenomenon?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Confounding"
        },
        {
          "id": 2,
          "text": "Effect modification"
        },
        {
          "id": 3,
          "text": "Latent period"
        },
        {
          "id": 4,
          "text": "Observer bias"
        },
        {
          "id": 5,
          "text": "Selection bias"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Confounding, effect modification, bias, errors</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Effect modification</strong> occurs when the effect of an exposure on an outcome is modified by another variable.&nbsp; It can be identified using <strong>stratified analysis</strong> (analyzing the cohort as different subgroups), as the different strata will have <strong>different measures of association</strong>.&nbsp; In this scenario, smoking status modified the effect of the new estrogen receptor agonist (exposure) on deep vein thrombosis (DVT) incidence (outcome).&nbsp; Using stratified analysis by smoking status:</p><ul><li>Among smokers, there was a statistically significant association between taking the new estrogen receptor agonist and risk of developing DVT with a relative risk of &gt;1, indicating higher risk, and a p-value of &lt;0.05, indicating statistical significance.</li><li>In contrast, among nonsmokers, there was no statistically significant association between taking the medication and risk of DVT (p-value &gt;0.05).</li></ul><p>Effect modification is not a bias <strong>(Choices D and E)</strong>, as it is not due to flaws in the design or analysis phases of the study.&nbsp; It is a natural phenomenon that should be described, not corrected.</p><p>Effect modification is most easily confused with <strong>confounding (Choice A)</strong>, but stratified analysis can help distinguish between these 2 scenarios.&nbsp; With effect modification, the different strata will have different measures of association, as seen in this example of the association between taking the estrogen receptor and the risk of DVT among smokers compared to nonsmokers.&nbsp; In contrast, with confounding, stratification usually reveals no significant difference between the strata.&nbsp; <a href=\"1943\">For instance</a>, in an analysis of primary school students (of all grade levels), age can be a confounder that muddies the association between shoe size and intelligence.&nbsp; Children with bigger shoe sizes may appear to be more intelligent on initial analysis.&nbsp; However, this association is likely not due to shoe size but rather to age because older children tend to have both bigger feet and more intelligence.&nbsp; When older and younger children are analyzed separately (stratification based on the confounder), the association between shoe size and intelligence disappears.</p><p><strong>(Choice C)</strong>&nbsp; The latent period is the time required for an exposure to begin having an effect.&nbsp; However, there is no information on how latency was handled in this study.</p><p><strong>Educational objective:</strong><br>Effect modification is present when the effect of the main exposure on the outcome is modified by the presence of another variable.&nbsp; Effect modification is not a bias.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1279",
      "difficulty": "N/A"
    },
    {
      "text": "<P>400 women aged 20-35 coming for routine check-up are asked about their smoking status. &nbsp;40% of the women are smokers.&nbsp; Over the next ten years, 25 smokers and 24 non-smokers developed breast cancer.&nbsp; Which of the following best describes the study design?</P>",
      "choices": [
        {
          "id": 1,
          "text": "Prospective cohort study"
        },
        {
          "id": 2,
          "text": "Retrospective cohort study"
        },
        {
          "id": 3,
          "text": "Case-control study"
        },
        {
          "id": 4,
          "text": "Cross-sectional study"
        },
        {
          "id": 5,
          "text": "Randomized clinical trial"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><P>The scenario described above is a good example of prospective cohort study.&nbsp; Initially a group of subjects is selected (i.e., cohort) and their exposure status is determined (smoker/non-smoker).&nbsp; The cohort is then followed for a certain period of time and observed for development of the outcome (breast cancer).&nbsp; Sometimes, the exposure status is determined retrospectively and then patients are tracked from that point of time, typically using medical records <B>(Choice B)</B>.</P><P><B>(Choice C) </B>A case-control study is designed by selecting patients with a particular disease (cases) and without that disease (controls) and then determining their previous exposure status.</P><P><B>(Choice D)</B> A cross-sectional study is also known as a prevalence study.&nbsp; It is characterized by the simultaneous measurement of exposure and outcome. &nbsp;It is a snapshot study design that frequently uses surveys.&nbsp; They are relatively inexpensive and easy to perform.</P><P><B>(Choice E) </B>A randomized clinical trial directly compares two or more treatments. &nbsp;Usually, the subjects are randomly assigned to an exposure (e.g., a medication) or placebo and then followed for the development of the outcome of interest.</P><P><B>Educational Objective:<BR></B>Prospective cohort studies are organized by selecting a group of individuals (i.e., cohort), determining their exposure status, and then following them over time for development of the disease of interest.</P>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1203",
      "difficulty": "N/A"
    },
    {
      "text": "<p>Researchers are studying the relationship between essential hypertension and a common mutation in the structure of a sodium channel protein.&nbsp; A study population is randomly selected and blood samples are obtained for leukocyte genotyping.&nbsp; The prevalence of hypertension is determined based on mean blood pressure measurements obtained using standardized ambulatory blood pressure monitoring conducted over 1 week.&nbsp; Based on the analysis results, the researchers conclude that the sodium channel structure mutation is associated with hypertension.&nbsp; Which of the following best describes the study design used by the investigators?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Case-control study"
        },
        {
          "id": 2,
          "text": "Cross-sectional study"
        },
        {
          "id": 3,
          "text": "Prospective cohort study"
        },
        {
          "id": 4,
          "text": "Randomized clinical trial"
        },
        {
          "id": 5,
          "text": "Retrospective cohort study"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > Study designs</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"6804\"  src=\"https://www.uworld.com/media/L13767.jpg\" draggable=\"false\" ></p><p>A <strong>cross-sectional</strong> study (also known as a prevalence study) simultaneously measures exposures and outcomes.&nbsp; The cross-sectional study has a &#x22;<strong>snapshot</strong>&#x22; design that is frequently used in surveys, mostly because it is inexpensive and easy to perform.&nbsp; In this example, a snapshot was obtained of individuals randomly selected from the population; their blood samples were analyzed for the presence of the sodium channel protein mutation and the prevalence of hypertension was calculated.&nbsp; The subjects&#39; blood pressure was measured over 7 days to obtain an average measurement (likely to limit the results being impacted by white-coat hypertension and other transient causes of hypertension).&nbsp; The major limitation of a cross-sectional study design is that a temporal relationship between exposure and outcome is not always clear.&nbsp; However, in this case, demonstrating a temporal relationship was straightforward because the possession of a specific genotype clearly precedes hypertension.</p><p><strong>(Choice A)</strong>&nbsp; A case-control study is designed by selecting individuals with a particular disease (cases), individuals without that disease (controls), and then evaluating previous exposure status.&nbsp; This study would have been classified as a case-control study if it had explicitly recruited individuals with (cases) and without (controls) hypertension (rather than randomly selecting a sample from a population) and evaluated their sodium channel mutation patterns.</p><p><strong>(Choices C and E)</strong>&nbsp; A prospective cohort study would have taken individuals without hypertension from the population, analyzed their blood samples to determine the distribution of the sodium channel mutation, and followed them over time (years) to determine the proportion of new cases of hypertension in patients with and without the mutation.&nbsp; In this example, although hypertension was measured over several days, the objective was not to document incidence of new cases of hypertension (which would be unlikely to develop over 1 week) but to measure the prevalence of hypertension while ensuring that average blood pressure measurements were obtained.</p><p>A retrospective design would have also assessed incidence (not prevalence) of hypertension compared to an earlier period of time, based on a chart review of historic data.&nbsp; Prospective and retrospective cohort studies are organized by selecting a group of individuals (ie, a cohort) who do <strong>not</strong> have the disease of interest (eg, hypertension), determining their exposure status, and then following them (forward in time or from a point in the past to the present) to assess for the development of the disease.</p><p><strong>(Choice D)</strong>&nbsp; A randomized clinical trial directly compares <u>&gt;</u>2 treatments.&nbsp; Usually, the subjects are randomly assigned to experience a specific exposure (eg, a medication) or no exposure (eg, placebo) and are then followed to assess for the outcome of interest (eg, disease).</p><p><strong>Educational objective:</strong><br>In a cross-sectional study, exposure and outcome are measured simultaneously at a particular point in time (&#x22;snapshot study&#x22;).&nbsp; In other study designs, a certain time period separates the exposure from the outcome.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1276",
      "difficulty": "N/A"
    },
    {
      "text": "<p>In a reference sample of hundreds of healthy subjects, the laboratory reference range for a novel marker of cardiac injury is 0.04-0.08 U/mL at the standard 95% level of probability.&nbsp; The marker has very high sensitivity and specificity for myocardial tissue.&nbsp; The clinical cardiology team would like to use a 99.7% reference range to assess patients who come to the emergency department with chest pain and have a high pretest probability of cardiac ischemia.&nbsp; An elevated value of the marker is defined as exceeding the 99.7th percentile of the reference sample.&nbsp; Assuming a normal (Gaussian) distribution with a mean of 0.06 U/mL, which of the following most closely approximates the corresponding reference range?</p>",
      "choices": [
        {
          "id": 1,
          "text": "0.03 to 0.09"
        },
        {
          "id": 2,
          "text": "0.035 to 0.085"
        },
        {
          "id": 3,
          "text": "0.045 to 0.075"
        },
        {
          "id": 4,
          "text": "0.05 to 0.07"
        },
        {
          "id": 5,
          "text": "0.055 to 0.065"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > P-value and confidence interval</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"14232\" src=\"https://www.uworld.com/media/L38991.jpg\" ></p><p>A <strong>normal (Gaussian) distribution</strong> refers to a symmetrical, bell-shaped distribution with a fixed proportion of observations lying within a certain distance of the mean.&nbsp; This distance is called the <strong>standard deviation (SD)</strong> and reflects the <strong>degree of dispersion</strong> from the mean.&nbsp; According to the properties of this distribution, 68% of observations lie within 1 SD from the mean, with half (ie, 68/2 = 34%) above and half (34%) below the mean.&nbsp; The remaining 32% (= 100% &#8722; 68%) lie outside 1 SD from the mean, with half (ie, 32/2 = 16%) above and the other half (16%) below 1 SD from the mean.&nbsp; In addition, 95% of all observations lie within 2 SD of the mean, and 99.7% of all observations lie within 3 SD from the mean.&nbsp; This is the <strong>68-95-99.7 rule</strong>.</p><p>The 95% range for this marker with a <strong>mean of 0.06</strong> U/mL is 0.04 to 0.08 U/mL; given a normal distribution, this represents the range given by mean &plusmn; 2 SD.&nbsp; Therefore, <strong>1 SD = 0.01</strong> (because 0.04 = mean &#8722; 2 SD = 0.06 &#8722; 2 SD = 0.06 &#8722; 2 &times; 0.01 and, similarly, 0.08 = 0.06 + 2 &times; 0.01).&nbsp; The <strong>99.7% range</strong> is given by <strong>mean &plusmn; 3 SD</strong>; therefore, the 99.7% range is <strong>0.03</strong> (= mean &#8722; 3 SD = 0.06 &#8722; 3 &times; 0.01) to <strong>0.09</strong> (= mean + 3 SD = 0.06 + 3 &times; 0.01).&nbsp; Any result that falls outside this range (eg, a value exceeding this range) indicates that the value is different from what is seen in 99.7% of the reference population.</p><p>In laboratory measurements, although 95% is often used as a reference range, a 99% range is used in certain cases (eg, to determine cutoff for troponin in acute myocardial infarction).&nbsp; Other laboratory analysis methods involve performing more specific calculations when it is important to detect a difference in one direction (eg, for a cancer marker, knowing that the value is significantly higher than normal is more important than knowing that it is significantly different&mdash;either higher or lower&mdash;than normal).&nbsp; In some cases, high-sensitivity assays (eg, high-sensitivity C-reactive protein testing) allow the detection of values in the lower range of normal, which would not have been possible with standard assays.</p><p><strong>Educational objective:</strong><br>In a normal (bell-shaped) distribution, 68% of all values are within 1 standard deviation (SD) from the mean; 95% are within 2 SD from the mean; and 99.7% are within 3 SD from the mean.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17646",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A researcher is interested in assessing the blood folate level of women who live in a population with a high incidence of neural tube defects.&nbsp; She takes a large random sample (<em>n</em>) of women age 18-45 and measures their blood folate levels.&nbsp; The researcher finds that the data are normally distributed, and she reports the mean and standard deviation (SD) of the sample.&nbsp; To account for sampling variation, she decides to calculate a 95% confidence interval to estimate the mean of the entire population.&nbsp; The researcher concludes that 2.4 to 4.6 ng/mL might be a likely range for the true, unknown population mean.&nbsp; Which of the following calculations was most likely used to compute this interval estimate of the population mean?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Mean &plusmn; 1.96 &times; SD"
        },
        {
          "id": 2,
          "text": "Mean &plusmn; 1.96 &times; (SD/&#8730;n)"
        },
        {
          "id": 3,
          "text": "Mean &plusmn; 2.58 &times; SD"
        },
        {
          "id": 4,
          "text": "Mean &plusmn; 2.58 &times; (SD/&#8730;n)"
        },
        {
          "id": 5,
          "text": "Mean &plusmn; (SD/n)"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biostatistics > Biostatistics & Epidemiology > P-value and confidence interval</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>The <strong>normal distribution</strong> is a continuous distribution that follows a bell-shaped curve with a single peak at the mean value.&nbsp; One of the most important properties of the normal distribution is its <strong>symmetry</strong> about its mean, which allows for determination of the percentage of all observations that lie within 1, 2, or 3 standard deviations (SDs).&nbsp; The <a href=\"1994\">&#x22;68/95/99 rule&#x22;</a> states that 68% of all observations lie within 1 SD of the mean, 95% within 2 SDs of the mean, and 99.7% within 3 SDs of the mean.&nbsp; These are helpful approximations; however, when considering the normal distribution, exactly <strong>95% of the observations</strong> lie within <strong>1.96 SDs</strong> of the mean and 99% of the observations lie within 2.58 SDs (1.96 and 2.58 represent <em>z</em>-scores for 95% and 99% of the distribution, respectively).</p><p>Most research is done using <strong>samples</strong> rather than entire populations.&nbsp; This introduces some variability when calculating population parameters such as mean value (eg, when different samples are drawn from the same population, the means from all possible samples will often be slightly different).&nbsp; The <strong>variability between sample means</strong> can be calculated in a way analogous to calculating the SD of a group of observations in a single sample.&nbsp; The &#x22;standard deviation&#x22; of a series of sample means is known as the <strong>standard error</strong> (<strong>SE</strong>) of the mean, and it estimates how far the sample mean is likely to be from the unknown population mean.&nbsp; The SE is estimated considering both the SD and the size of the sample (<em>n</em>) in the following manner:&nbsp; <strong>SD/&#8730;<em>n</em></strong>.</p><p>A sample mean is a point estimate of the true population mean; however, a <strong>confidence interval</strong> (<strong>CI</strong>) better accounts for the variability due to sampling by including the SE in its calculation.&nbsp; The CI of the mean can be calculated as follows:</p><p align=\"center\">CI of mean = mean &plusmn; [<em>z</em>-score for confidence level] &times; [SE]</p><p>where the <em>z</em>-score for confidence level represents the number of SEs containing the desired percentage of observations around the mean (eg, 95%, 99%).&nbsp; In this case, the 95% CI can be calculated:</p><p align=\"center\">CI of mean = <strong>mean &plusmn; 1.96 &times; (SD/&#8730;<em>n</em>)</strong></p><p>The sample size and the SD of the sample determine the magnitude of the variability due to sampling.&nbsp; As <em>n</em> increases, SE decreases, and the CI becomes narrower and more precise.&nbsp; Conversely, as the SD increases, SE increases, and the CI becomes wider and less precise.</p><p><strong>(Choice A)</strong>&nbsp; CI estimates use the SE of the mean, which takes into account the SD and the size of the sample (<em>n</em>).&nbsp; As such, the equation divides the SD by the square root of <em>n</em>.</p><p><strong>(Choices C, D, and E)</strong>&nbsp; As noted, the SD reflects the spread of individual values in a normal distribution.&nbsp; Multiplying the SD by a specific constant (<em>z</em>-score) gives us a range of values that encompass a certain proportion of the observations.&nbsp; The mean &plusmn; 1 &times; SD would cover 68% of the observations, and the mean &plusmn; 2.58 &times; SD would cover 99% of the observations.&nbsp; However, the question is asking for a 95% CI, so the equation should use a <em>z</em>-score of 1.96 and the SE (ie, SD/&#8730;<em>n</em>).</p><p><strong>Educational objective:</strong><br>The standard deviation reflects the spread of individual values in a normal distribution (ie, it measures the variability of the observations within a single sample).&nbsp; The standard error of the mean reflects the variability of means (ie, variance between the means of different samples) and helps estimate the true mean of the underlying population.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1299",
      "difficulty": "N/A"
    }
  ]
}